Re: Lilly Stock Spirals Down (Time for a little celebration!)

October 27, 2004

I hate for people to lose jobs but I love this news. goes to show

what unethical and harmful products will get a business everytime.

Couldn't happen to a better bunch. Makes me think carefully about

where I will work.

>

> http://www.indystar.com/articles/3/189440-8983-223.html

>

> Lilly stock spirals down

> The Indianapolis company's share price has hit a 52-week low every day

since

> Oct. 19.

>

> By J.K. Wall

> jk.wall@...

> October 26, 2004

>

> Eli Lilly and Co. shares hit another 52-week low Monday as the company

> continued to feel the fallout from its own weak financial growth and that

of

> the whole pharmaceutical industry.

>

> Shares of the Indianapolis-based company have fallen nearly 15 percent in

> the past two weeks, closing Monday at $50.44 a share. The value has fallen

> by more than 28 percent since Jan. 1. Lilly stock closed as high as $76.95

> in early June.

>

> The share price has hit a new 52-week low every day since Oct. 19. Lilly,

> Central Indiana's largest private employer, last week announced job cuts

and

> reported sales that disappointed Wall Street analysts.

>

> If the difficulties at Lilly are prolonged, they could indirectly affect

the

> Lilly Endowment, a massive Indianapolis philanthropic foundation.

>

> While the $10.8 billion endowment is independent of the drug maker, Lilly

> stock is the endowment's most significant asset.

>

> For now, however, the company's performance should not change the

> endowment's level of giving, said an official with the Indiana Grantmakers

> Alliance.

>

> " Private foundations are obligated to pay out at least 5 percent of their

> assets. However, the 5 percent is based on a three-year rolling average, "

> said Audette, vice president of the alliance, in a written

> statement. " Therefore a spike one way or the other in the market or in a

> particular stock, even if a foundation is heavy in that stock, has little

> effect on the long-term giving. "

> Other drug companies also aren't faring well on Wall Street.

>

> Last week was the fifth straight that the American Stock Exchange

> Pharmaceutical Index fell. The slide started just before Merck & Co Inc.

> announced that it would yank Vioxx, a popular arthritis drug, from the

> market. Hazlett, a pharmaceuticals analyst at SunTrust

> Humphrey, described that development as a " disaster " for Merck that has

> affected the entire industry.

>

> Pfizer, the world's largest drug maker, disappointed investors last week

> with revenues that missed analysts' estimates. Its profits beat estimates

by

> a penny per share, but it also warned that next year's results could be

hurt

> by the arrival of generic competitors against four of its drugs.

> GlaxoKline, which reports earnings Thursday, faces several cheaper

> copycat medications that will compete with its compounds.

>

> In addition, Hazlett said, pharmaceutical companies also fear that a

victory

> by presidential candidate Kerry would lead to lower drug prices and

> imported drugs from Canada. Kerry has said he wants government health care

> programs to negotiate lower prices with drug companies.

>

> " The specter of a Democratic administration has had some effect on the

> stocks, " Hazlett said.

> Politics aside, Lilly has struggled to keep sales up and costs down.

>

> In the past two weeks, Lilly has announced it would cut 1,000 jobs from

its

> work force, which numbers 46,000 worldwide. Lilly's operations in

> Indianapolis will absorb 225. Lilly also instituted a hiring freeze in

> August.

>

> Those cost-cutting moves helped Lilly post a 6 percent increase in profits

> in its fiscal third quarter; revenue grew a modest 4 percent, leaving Wall

> Street nonplussed.

>

> " The good news is management had the 'wiggle room' -- the bad news is they

> needed it (and likely will continue to), " wrote Carl Seiden, an analyst

> covering Lilly for the brokerage firm UBS.

>

> Many analysts are worried by declining sales of Lilly's blockbuster drug,

> Zyprexa. It generates more than $4 billion a year for Lilly, and, by some

> analysts' estimates, accounts for 60 percent of the company's profits.

>

> Sales of the antipsychotic drug fell 9 percent in Lilly's third quarter,

> including a 22 percent drop in the United States. And the patent challenge

> brought against Zyprexa by a generic drug maker, which is now in the hands

> of an Indianapolis judge, still hangs like a cloud over Lilly.

>

> " We believe investors are better off on the sidelines until the visibility

> on the Zyprexa controversies improve, " Seiden wrote.

>

> Other analysts have been disappointed in early sales of Lilly's newest

> drugs, such as Strattera, which is used in treating attention-deficit

> hyperactivity disorder.

>

> But Hazlett takes a rosier view on Lilly. He points to Cymbalta, an

> antidepressant Lilly rolled out this summer, as evidence for his

prediction

> of strong profit growth the next two years.

>

> Hazlett wrote that he " would recommend that investors use the recent

> weakness to establish or add to a position. "

>

> Star reporter O'Neal contributed to this story.

> Call Star reporter J.K. Wall at (317) 444-6287.

>

October 27, 2004

I hate for people to lose jobs but I love this news. goes to show

what unethical and harmful products will get a business everytime.

Couldn't happen to a better bunch. Makes me think carefully about

where I will work.

>

> http://www.indystar.com/articles/3/189440-8983-223.html

>

> Lilly stock spirals down

> The Indianapolis company's share price has hit a 52-week low every day

since

> Oct. 19.

>

> By J.K. Wall

> jk.wall@...

> October 26, 2004

>

> Eli Lilly and Co. shares hit another 52-week low Monday as the company

> continued to feel the fallout from its own weak financial growth and that

of

> the whole pharmaceutical industry.

>

> Shares of the Indianapolis-based company have fallen nearly 15 percent in

> the past two weeks, closing Monday at $50.44 a share. The value has fallen

> by more than 28 percent since Jan. 1. Lilly stock closed as high as $76.95

> in early June.

>

> The share price has hit a new 52-week low every day since Oct. 19. Lilly,

> Central Indiana's largest private employer, last week announced job cuts

and

> reported sales that disappointed Wall Street analysts.

>

> If the difficulties at Lilly are prolonged, they could indirectly affect

the

> Lilly Endowment, a massive Indianapolis philanthropic foundation.

>

> While the $10.8 billion endowment is independent of the drug maker, Lilly

> stock is the endowment's most significant asset.

>

> For now, however, the company's performance should not change the

> endowment's level of giving, said an official with the Indiana Grantmakers

> Alliance.

>

> " Private foundations are obligated to pay out at least 5 percent of their

> assets. However, the 5 percent is based on a three-year rolling average, "

> said Audette, vice president of the alliance, in a written

> statement. " Therefore a spike one way or the other in the market or in a

> particular stock, even if a foundation is heavy in that stock, has little

> effect on the long-term giving. "

> Other drug companies also aren't faring well on Wall Street.

>

> Last week was the fifth straight that the American Stock Exchange

> Pharmaceutical Index fell. The slide started just before Merck & Co Inc.

> announced that it would yank Vioxx, a popular arthritis drug, from the

> market. Hazlett, a pharmaceuticals analyst at SunTrust

> Humphrey, described that development as a " disaster " for Merck that has

> affected the entire industry.

>

> Pfizer, the world's largest drug maker, disappointed investors last week

> with revenues that missed analysts' estimates. Its profits beat estimates

by

> a penny per share, but it also warned that next year's results could be

hurt

> by the arrival of generic competitors against four of its drugs.

> GlaxoKline, which reports earnings Thursday, faces several cheaper

> copycat medications that will compete with its compounds.

>

> In addition, Hazlett said, pharmaceutical companies also fear that a

victory

> by presidential candidate Kerry would lead to lower drug prices and

> imported drugs from Canada. Kerry has said he wants government health care

> programs to negotiate lower prices with drug companies.

>

> " The specter of a Democratic administration has had some effect on the

> stocks, " Hazlett said.

> Politics aside, Lilly has struggled to keep sales up and costs down.

>

> In the past two weeks, Lilly has announced it would cut 1,000 jobs from

its

> work force, which numbers 46,000 worldwide. Lilly's operations in

> Indianapolis will absorb 225. Lilly also instituted a hiring freeze in

> August.

>

> Those cost-cutting moves helped Lilly post a 6 percent increase in profits

> in its fiscal third quarter; revenue grew a modest 4 percent, leaving Wall

> Street nonplussed.

>

> " The good news is management had the 'wiggle room' -- the bad news is they

> needed it (and likely will continue to), " wrote Carl Seiden, an analyst

> covering Lilly for the brokerage firm UBS.

>

> Many analysts are worried by declining sales of Lilly's blockbuster drug,

> Zyprexa. It generates more than $4 billion a year for Lilly, and, by some

> analysts' estimates, accounts for 60 percent of the company's profits.

>

> Sales of the antipsychotic drug fell 9 percent in Lilly's third quarter,

> including a 22 percent drop in the United States. And the patent challenge

> brought against Zyprexa by a generic drug maker, which is now in the hands

> of an Indianapolis judge, still hangs like a cloud over Lilly.

>

> " We believe investors are better off on the sidelines until the visibility

> on the Zyprexa controversies improve, " Seiden wrote.

>

> Other analysts have been disappointed in early sales of Lilly's newest

> drugs, such as Strattera, which is used in treating attention-deficit

> hyperactivity disorder.

>

> But Hazlett takes a rosier view on Lilly. He points to Cymbalta, an

> antidepressant Lilly rolled out this summer, as evidence for his

prediction

> of strong profit growth the next two years.

>

> Hazlett wrote that he " would recommend that investors use the recent

> weakness to establish or add to a position. "

>

> Star reporter O'Neal contributed to this story.

> Call Star reporter J.K. Wall at (317) 444-6287.

>

October 27, 2004

Dear Jim, Can you send this without all the >'s

A good companion to the financial expose i just sent bout SSRi's effect on

my family Re: Lilly Stock Spirals Down (Time for a little

celebration!)

>

> I hate for people to lose jobs but I love this news. goes to show

> what unethical and harmful products will get a business everytime.

> Couldn't happen to a better bunch. Makes me think carefully about

> where I will work.

>

> >

> > http://www.indystar.com/articles/3/189440-8983-223.html

> >

> > Lilly stock spirals down

> > The Indianapolis company's share price has hit a 52-week low every day

> since

> > Oct. 19.

> >

> > By J.K. Wall

> > jk.wall@...

> > October 26, 2004

> >

> > Eli Lilly and Co. shares hit another 52-week low Monday as the company

> > continued to feel the fallout from its own weak financial growth and

that

> of

> > the whole pharmaceutical industry.

> >

> > Shares of the Indianapolis-based company have fallen nearly 15 percent

in

> > the past two weeks, closing Monday at $50.44 a share. The value has

fallen

> > by more than 28 percent since Jan. 1. Lilly stock closed as high as

$76.95

> > in early June.

> >

> > The share price has hit a new 52-week low every day since Oct. 19.

Lilly,

> > Central Indiana's largest private employer, last week announced job cuts

> and

> > reported sales that disappointed Wall Street analysts.

> >

> > If the difficulties at Lilly are prolonged, they could indirectly affect

> the

> > Lilly Endowment, a massive Indianapolis philanthropic foundation.

> >

> > While the $10.8 billion endowment is independent of the drug maker,

Lilly

> > stock is the endowment's most significant asset.

> >

> > For now, however, the company's performance should not change the

> > endowment's level of giving, said an official with the Indiana

Grantmakers

> > Alliance.

> >

> > " Private foundations are obligated to pay out at least 5 percent of

their

> > assets. However, the 5 percent is based on a three-year rolling

average, "

> > said Audette, vice president of the alliance, in a written

> > statement. " Therefore a spike one way or the other in the market or in a

> > particular stock, even if a foundation is heavy in that stock, has

little

> > effect on the long-term giving. "

> > Other drug companies also aren't faring well on Wall Street.

> >

> > Last week was the fifth straight that the American Stock Exchange

> > Pharmaceutical Index fell. The slide started just before Merck & Co Inc.

> > announced that it would yank Vioxx, a popular arthritis drug, from the

> > market. Hazlett, a pharmaceuticals analyst at SunTrust

> > Humphrey, described that development as a " disaster " for Merck that has

> > affected the entire industry.

> >

> > Pfizer, the world's largest drug maker, disappointed investors last week

> > with revenues that missed analysts' estimates. Its profits beat

estimates

> by

> > a penny per share, but it also warned that next year's results could be

> hurt

> > by the arrival of generic competitors against four of its drugs.

> > GlaxoKline, which reports earnings Thursday, faces several cheaper

> > copycat medications that will compete with its compounds.

> >

> > In addition, Hazlett said, pharmaceutical companies also fear that a

> victory

> > by presidential candidate Kerry would lead to lower drug prices and

> > imported drugs from Canada. Kerry has said he wants government health

care

> > programs to negotiate lower prices with drug companies.

> >

> > " The specter of a Democratic administration has had some effect on the

> > stocks, " Hazlett said.

> > Politics aside, Lilly has struggled to keep sales up and costs down.

> >

> > In the past two weeks, Lilly has announced it would cut 1,000 jobs from

> its

> > work force, which numbers 46,000 worldwide. Lilly's operations in

> > Indianapolis will absorb 225. Lilly also instituted a hiring freeze in

> > August.

> >

> > Those cost-cutting moves helped Lilly post a 6 percent increase in

profits

> > in its fiscal third quarter; revenue grew a modest 4 percent, leaving

Wall

> > Street nonplussed.

> >

> > " The good news is management had the 'wiggle room' -- the bad news is

they

> > needed it (and likely will continue to), " wrote Carl Seiden, an analyst

> > covering Lilly for the brokerage firm UBS.

> >

> > Many analysts are worried by declining sales of Lilly's blockbuster

drug,

> > Zyprexa. It generates more than $4 billion a year for Lilly, and, by

some

> > analysts' estimates, accounts for 60 percent of the company's profits.

> >

> > Sales of the antipsychotic drug fell 9 percent in Lilly's third quarter,

> > including a 22 percent drop in the United States. And the patent

challenge

> > brought against Zyprexa by a generic drug maker, which is now in the

hands

> > of an Indianapolis judge, still hangs like a cloud over Lilly.

> >

> > " We believe investors are better off on the sidelines until the

visibility

> > on the Zyprexa controversies improve, " Seiden wrote.

> >

> > Other analysts have been disappointed in early sales of Lilly's newest

> > drugs, such as Strattera, which is used in treating attention-deficit

> > hyperactivity disorder.

> >

> > But Hazlett takes a rosier view on Lilly. He points to Cymbalta, an

> > antidepressant Lilly rolled out this summer, as evidence for his

> prediction

> > of strong profit growth the next two years.

> >

> > Hazlett wrote that he " would recommend that investors use the recent

> > weakness to establish or add to a position. "

> >

> > Star reporter O'Neal contributed to this story.

> > Call Star reporter J.K. Wall at (317) 444-6287.

> >

October 27, 2004

Dear Jim, Can you send this without all the >'s

A good companion to the financial expose i just sent bout SSRi's effect on

my family Re: Lilly Stock Spirals Down (Time for a little

celebration!)

>

> I hate for people to lose jobs but I love this news. goes to show

> what unethical and harmful products will get a business everytime.

> Couldn't happen to a better bunch. Makes me think carefully about

> where I will work.

>

> >

> > http://www.indystar.com/articles/3/189440-8983-223.html

> >

> > Lilly stock spirals down

> > The Indianapolis company's share price has hit a 52-week low every day

> since

> > Oct. 19.

> >

> > By J.K. Wall

> > jk.wall@...

> > October 26, 2004

> >

> > Eli Lilly and Co. shares hit another 52-week low Monday as the company

> > continued to feel the fallout from its own weak financial growth and

that

> of

> > the whole pharmaceutical industry.

> >

> > Shares of the Indianapolis-based company have fallen nearly 15 percent

in

> > the past two weeks, closing Monday at $50.44 a share. The value has

fallen

> > by more than 28 percent since Jan. 1. Lilly stock closed as high as

$76.95

> > in early June.

> >

> > The share price has hit a new 52-week low every day since Oct. 19.

Lilly,

> > Central Indiana's largest private employer, last week announced job cuts

> and

> > reported sales that disappointed Wall Street analysts.

> >

> > If the difficulties at Lilly are prolonged, they could indirectly affect

> the

> > Lilly Endowment, a massive Indianapolis philanthropic foundation.

> >

> > While the $10.8 billion endowment is independent of the drug maker,

Lilly

> > stock is the endowment's most significant asset.

> >

> > For now, however, the company's performance should not change the

> > endowment's level of giving, said an official with the Indiana

Grantmakers

> > Alliance.

> >

> > " Private foundations are obligated to pay out at least 5 percent of

their

> > assets. However, the 5 percent is based on a three-year rolling

average, "

> > said Audette, vice president of the alliance, in a written

> > statement. " Therefore a spike one way or the other in the market or in a

> > particular stock, even if a foundation is heavy in that stock, has

little

> > effect on the long-term giving. "

> > Other drug companies also aren't faring well on Wall Street.

> >

> > Last week was the fifth straight that the American Stock Exchange

> > Pharmaceutical Index fell. The slide started just before Merck & Co Inc.

> > announced that it would yank Vioxx, a popular arthritis drug, from the

> > market. Hazlett, a pharmaceuticals analyst at SunTrust

> > Humphrey, described that development as a " disaster " for Merck that has

> > affected the entire industry.

> >

> > Pfizer, the world's largest drug maker, disappointed investors last week

> > with revenues that missed analysts' estimates. Its profits beat

estimates

> by

> > a penny per share, but it also warned that next year's results could be

> hurt

> > by the arrival of generic competitors against four of its drugs.

> > GlaxoKline, which reports earnings Thursday, faces several cheaper

> > copycat medications that will compete with its compounds.

> >

> > In addition, Hazlett said, pharmaceutical companies also fear that a

> victory

> > by presidential candidate Kerry would lead to lower drug prices and

> > imported drugs from Canada. Kerry has said he wants government health

care

> > programs to negotiate lower prices with drug companies.

> >

> > " The specter of a Democratic administration has had some effect on the

> > stocks, " Hazlett said.

> > Politics aside, Lilly has struggled to keep sales up and costs down.

> >

> > In the past two weeks, Lilly has announced it would cut 1,000 jobs from

> its

> > work force, which numbers 46,000 worldwide. Lilly's operations in

> > Indianapolis will absorb 225. Lilly also instituted a hiring freeze in

> > August.

> >

> > Those cost-cutting moves helped Lilly post a 6 percent increase in

profits

> > in its fiscal third quarter; revenue grew a modest 4 percent, leaving

Wall

> > Street nonplussed.

> >

> > " The good news is management had the 'wiggle room' -- the bad news is

they

> > needed it (and likely will continue to), " wrote Carl Seiden, an analyst

> > covering Lilly for the brokerage firm UBS.

> >

> > Many analysts are worried by declining sales of Lilly's blockbuster

drug,

> > Zyprexa. It generates more than $4 billion a year for Lilly, and, by

some

> > analysts' estimates, accounts for 60 percent of the company's profits.

> >

> > Sales of the antipsychotic drug fell 9 percent in Lilly's third quarter,

> > including a 22 percent drop in the United States. And the patent

challenge

> > brought against Zyprexa by a generic drug maker, which is now in the

hands

> > of an Indianapolis judge, still hangs like a cloud over Lilly.

> >

> > " We believe investors are better off on the sidelines until the

visibility

> > on the Zyprexa controversies improve, " Seiden wrote.

> >

> > Other analysts have been disappointed in early sales of Lilly's newest

> > drugs, such as Strattera, which is used in treating attention-deficit

> > hyperactivity disorder.

> >

> > But Hazlett takes a rosier view on Lilly. He points to Cymbalta, an

> > antidepressant Lilly rolled out this summer, as evidence for his

> prediction

> > of strong profit growth the next two years.

> >

> > Hazlett wrote that he " would recommend that investors use the recent

> > weakness to establish or add to a position. "

> >

> > Star reporter O'Neal contributed to this story.

> > Call Star reporter J.K. Wall at (317) 444-6287.

> >

October 27, 2004

Nope. Your best bet is to go back to the original post that I commented on

or

click on the link to the article. What your asking is that I edit out all

the >'s by hand

and I'm not gonna do it

Best,

Jim

Re: Lilly Stock Spirals Down (Time for a little

> celebration!)

>

> >

> > I hate for people to lose jobs but I love this news. goes to show

> > what unethical and harmful products will get a business everytime.

> > Couldn't happen to a better bunch. Makes me think carefully about

> > where I will work.

> >

> > >

> > > http://www.indystar.com/articles/3/189440-8983-223.html

> > >

> > > Lilly stock spirals down

> > > The Indianapolis company's share price has hit a 52-week low every day

> > since

> > > Oct. 19.

> > >

> > > By J.K. Wall

> > > jk.wall@...

> > > October 26, 2004

> > >

> > > Eli Lilly and Co. shares hit another 52-week low Monday as the company

> > > continued to feel the fallout from its own weak financial growth and

> that

> > of

> > > the whole pharmaceutical industry.

> > >

> > > Shares of the Indianapolis-based company have fallen nearly 15 percent

> in

> > > the past two weeks, closing Monday at $50.44 a share. The value has

> fallen

> > > by more than 28 percent since Jan. 1. Lilly stock closed as high as

> $76.95

> > > in early June.

> > >

> > > The share price has hit a new 52-week low every day since Oct. 19.

> Lilly,

> > > Central Indiana's largest private employer, last week announced job

cuts

> > and

> > > reported sales that disappointed Wall Street analysts.

> > >

> > > If the difficulties at Lilly are prolonged, they could indirectly

affect

> > the

> > > Lilly Endowment, a massive Indianapolis philanthropic foundation.

> > >

> > > While the $10.8 billion endowment is independent of the drug maker,

> Lilly

> > > stock is the endowment's most significant asset.

> > >

> > > For now, however, the company's performance should not change the

> > > endowment's level of giving, said an official with the Indiana

> Grantmakers

> > > Alliance.

> > >

> > > " Private foundations are obligated to pay out at least 5 percent of

> their

> > > assets. However, the 5 percent is based on a three-year rolling

> average, "

> > > said Audette, vice president of the alliance, in a written

> > > statement. " Therefore a spike one way or the other in the market or in

a

> > > particular stock, even if a foundation is heavy in that stock, has

> little

> > > effect on the long-term giving. "

> > > Other drug companies also aren't faring well on Wall Street.

> > >

> > > Last week was the fifth straight that the American Stock Exchange

> > > Pharmaceutical Index fell. The slide started just before Merck & Co

Inc.

> > > announced that it would yank Vioxx, a popular arthritis drug, from the

> > > market. Hazlett, a pharmaceuticals analyst at SunTrust

> > > Humphrey, described that development as a " disaster " for Merck that

has

> > > affected the entire industry.

> > >

> > > Pfizer, the world's largest drug maker, disappointed investors last

week

> > > with revenues that missed analysts' estimates. Its profits beat

> estimates

> > by

> > > a penny per share, but it also warned that next year's results could

be

> > hurt

> > > by the arrival of generic competitors against four of its drugs.

> > > GlaxoKline, which reports earnings Thursday, faces several

cheaper

> > > copycat medications that will compete with its compounds.

> > >

> > > In addition, Hazlett said, pharmaceutical companies also fear that a

> > victory

> > > by presidential candidate Kerry would lead to lower drug prices

and

> > > imported drugs from Canada. Kerry has said he wants government health

> care

> > > programs to negotiate lower prices with drug companies.

> > >

> > > " The specter of a Democratic administration has had some effect on the

> > > stocks, " Hazlett said.

> > > Politics aside, Lilly has struggled to keep sales up and costs down.

> > >

> > > In the past two weeks, Lilly has announced it would cut 1,000 jobs

from

> > its

> > > work force, which numbers 46,000 worldwide. Lilly's operations in

> > > Indianapolis will absorb 225. Lilly also instituted a hiring freeze in

> > > August.

> > >

> > > Those cost-cutting moves helped Lilly post a 6 percent increase in

> profits

> > > in its fiscal third quarter; revenue grew a modest 4 percent, leaving

> Wall

> > > Street nonplussed.

> > >

> > > " The good news is management had the 'wiggle room' -- the bad news is

> they

> > > needed it (and likely will continue to), " wrote Carl Seiden, an

analyst

> > > covering Lilly for the brokerage firm UBS.

> > >

> > > Many analysts are worried by declining sales of Lilly's blockbuster

> drug,

> > > Zyprexa. It generates more than $4 billion a year for Lilly, and, by

> some

> > > analysts' estimates, accounts for 60 percent of the company's profits.

> > >

> > > Sales of the antipsychotic drug fell 9 percent in Lilly's third

quarter,

> > > including a 22 percent drop in the United States. And the patent

> challenge

> > > brought against Zyprexa by a generic drug maker, which is now in the

> hands

> > > of an Indianapolis judge, still hangs like a cloud over Lilly.

> > >

> > > " We believe investors are better off on the sidelines until the

> visibility

> > > on the Zyprexa controversies improve, " Seiden wrote.

> > >

> > > Other analysts have been disappointed in early sales of Lilly's newest

> > > drugs, such as Strattera, which is used in treating attention-deficit

> > > hyperactivity disorder.

> > >

> > > But Hazlett takes a rosier view on Lilly. He points to Cymbalta, an

> > > antidepressant Lilly rolled out this summer, as evidence for his

> > prediction

> > > of strong profit growth the next two years.

> > >

> > > Hazlett wrote that he " would recommend that investors use the recent

> > > weakness to establish or add to a position. "

> > >

> > > Star reporter O'Neal contributed to this story.

> > > Call Star reporter J.K. Wall at (317) 444-6287.

> > >

October 27, 2004

Nope. Your best bet is to go back to the original post that I commented on

or

click on the link to the article. What your asking is that I edit out all

the >'s by hand

and I'm not gonna do it

Best,

Jim

Re: Lilly Stock Spirals Down (Time for a little

> celebration!)

>

> >

> > I hate for people to lose jobs but I love this news. goes to show

> > what unethical and harmful products will get a business everytime.

> > Couldn't happen to a better bunch. Makes me think carefully about

> > where I will work.

> >

> > >

> > > http://www.indystar.com/articles/3/189440-8983-223.html

> > >

> > > Lilly stock spirals down

> > > The Indianapolis company's share price has hit a 52-week low every day

> > since

> > > Oct. 19.

> > >

> > > By J.K. Wall

> > > jk.wall@...

> > > October 26, 2004

> > >

> > > Eli Lilly and Co. shares hit another 52-week low Monday as the company

> > > continued to feel the fallout from its own weak financial growth and

> that

> > of

> > > the whole pharmaceutical industry.

> > >

> > > Shares of the Indianapolis-based company have fallen nearly 15 percent

> in

> > > the past two weeks, closing Monday at $50.44 a share. The value has

> fallen

> > > by more than 28 percent since Jan. 1. Lilly stock closed as high as

> $76.95

> > > in early June.

> > >

> > > The share price has hit a new 52-week low every day since Oct. 19.

> Lilly,

> > > Central Indiana's largest private employer, last week announced job

cuts

> > and

> > > reported sales that disappointed Wall Street analysts.

> > >

> > > If the difficulties at Lilly are prolonged, they could indirectly

affect

> > the

> > > Lilly Endowment, a massive Indianapolis philanthropic foundation.

> > >

> > > While the $10.8 billion endowment is independent of the drug maker,

> Lilly

> > > stock is the endowment's most significant asset.

> > >

> > > For now, however, the company's performance should not change the

> > > endowment's level of giving, said an official with the Indiana

> Grantmakers

> > > Alliance.

> > >

> > > " Private foundations are obligated to pay out at least 5 percent of

> their

> > > assets. However, the 5 percent is based on a three-year rolling

> average, "

> > > said Audette, vice president of the alliance, in a written

> > > statement. " Therefore a spike one way or the other in the market or in

a

> > > particular stock, even if a foundation is heavy in that stock, has

> little

> > > effect on the long-term giving. "

> > > Other drug companies also aren't faring well on Wall Street.

> > >

> > > Last week was the fifth straight that the American Stock Exchange

> > > Pharmaceutical Index fell. The slide started just before Merck & Co

Inc.

> > > announced that it would yank Vioxx, a popular arthritis drug, from the

> > > market. Hazlett, a pharmaceuticals analyst at SunTrust

> > > Humphrey, described that development as a " disaster " for Merck that

has

> > > affected the entire industry.

> > >

> > > Pfizer, the world's largest drug maker, disappointed investors last

week

> > > with revenues that missed analysts' estimates. Its profits beat

> estimates

> > by

> > > a penny per share, but it also warned that next year's results could

be

> > hurt

> > > by the arrival of generic competitors against four of its drugs.

> > > GlaxoKline, which reports earnings Thursday, faces several

cheaper

> > > copycat medications that will compete with its compounds.

> > >

> > > In addition, Hazlett said, pharmaceutical companies also fear that a

> > victory

> > > by presidential candidate Kerry would lead to lower drug prices

and

> > > imported drugs from Canada. Kerry has said he wants government health

> care

> > > programs to negotiate lower prices with drug companies.

> > >

> > > " The specter of a Democratic administration has had some effect on the

> > > stocks, " Hazlett said.

> > > Politics aside, Lilly has struggled to keep sales up and costs down.

> > >

> > > In the past two weeks, Lilly has announced it would cut 1,000 jobs

from

> > its

> > > work force, which numbers 46,000 worldwide. Lilly's operations in

> > > Indianapolis will absorb 225. Lilly also instituted a hiring freeze in

> > > August.

> > >

> > > Those cost-cutting moves helped Lilly post a 6 percent increase in

> profits

> > > in its fiscal third quarter; revenue grew a modest 4 percent, leaving

> Wall

> > > Street nonplussed.

> > >

> > > " The good news is management had the 'wiggle room' -- the bad news is

> they

> > > needed it (and likely will continue to), " wrote Carl Seiden, an

analyst

> > > covering Lilly for the brokerage firm UBS.

> > >

> > > Many analysts are worried by declining sales of Lilly's blockbuster

> drug,

> > > Zyprexa. It generates more than $4 billion a year for Lilly, and, by

> some

> > > analysts' estimates, accounts for 60 percent of the company's profits.

> > >

> > > Sales of the antipsychotic drug fell 9 percent in Lilly's third

quarter,

> > > including a 22 percent drop in the United States. And the patent

> challenge

> > > brought against Zyprexa by a generic drug maker, which is now in the

> hands

> > > of an Indianapolis judge, still hangs like a cloud over Lilly.

> > >

> > > " We believe investors are better off on the sidelines until the

> visibility

> > > on the Zyprexa controversies improve, " Seiden wrote.

> > >

> > > Other analysts have been disappointed in early sales of Lilly's newest

> > > drugs, such as Strattera, which is used in treating attention-deficit

> > > hyperactivity disorder.

> > >

> > > But Hazlett takes a rosier view on Lilly. He points to Cymbalta, an

> > > antidepressant Lilly rolled out this summer, as evidence for his

> > prediction

> > > of strong profit growth the next two years.

> > >

> > > Hazlett wrote that he " would recommend that investors use the recent

> > > weakness to establish or add to a position. "

> > >

> > > Star reporter O'Neal contributed to this story.

> > > Call Star reporter J.K. Wall at (317) 444-6287.

> > >

October 27, 2004

funny, oh come on Jim. lololololol. i'm sorry, but

this is to funny. lololololol Why not????

Connie

--- Jim <mofunnow@...> wrote:

---------------------------------

Nope. Your best bet is to go back to the original post

that I commented on

or

click on the link to the article. What your asking is

that I edit out all

the >'s by hand

and I'm not gonna do it

Best,

Jim

Re: Lilly Stock Spirals

Down (Time for a little

> celebration!)

>

> >

> > I hate for people to lose jobs but I love this

news. goes to show

> > what unethical and harmful products will get a

business everytime.

> > Couldn't happen to a better bunch. Makes me think

carefully about

> > where I will work.

> >

> > >

http://www.indystar.com/articles/3/189440-8983-223.html

> > >

> > > Lilly stock spirals down

> > > The Indianapolis company's share price has hit a

52-week low every day

> > since

> > > Oct. 19.

> > >

> > > By J.K. Wall

> > > jk.wall@...

> > > October 26, 2004

> > >

> > > Eli Lilly and Co. shares hit another 52-week low

Monday as the company

> > > continued to feel the fallout from its own weak

financial growth and

> that

> > of

> > > the whole pharmaceutical industry.

> > >

> > > Shares of the Indianapolis-based company have

fallen nearly 15 percent

> in

> > > the past two weeks, closing Monday at $50.44 a

share. The value has

> fallen

> > > by more than 28 percent since Jan. 1. Lilly

stock closed as high as

> $76.95

> > > in early June.

> > >

> > > The share price has hit a new 52-week low every

day since Oct. 19.

> Lilly,

> > > Central Indiana's largest private employer, last

week announced job

cuts

> > and

> > > reported sales that disappointed Wall Street

analysts.

> > >

> > > If the difficulties at Lilly are prolonged, they

could indirectly

affect

> > the

> > > Lilly Endowment, a massive Indianapolis

philanthropic foundation.

> > >

> > > While the $10.8 billion endowment is independent

of the drug maker,

> Lilly

> > > stock is the endowment's most significant asset.

> > >

> > > For now, however, the company's performance

should not change the

> > > endowment's level of giving, said an official

with the Indiana

> Grantmakers

> > > Alliance.

> > >

> > > " Private foundations are obligated to pay out at

least 5 percent of

> their

> > > assets. However, the 5 percent is based on a

three-year rolling

> average, "

> > > said Audette, vice president of the

alliance, in a written

> > > statement. " Therefore a spike one way or the

other in the market or in

a

> > > particular stock, even if a foundation is heavy

in that stock, has

> little

> > > effect on the long-term giving. "

> > > Other drug companies also aren't faring well on

Wall Street.

> > >

> > > Last week was the fifth straight that the

American Stock Exchange

> > > Pharmaceutical Index fell. The slide started

just before Merck & Co

Inc.

> > > announced that it would yank Vioxx, a popular

arthritis drug, from the

> > > market. Hazlett, a pharmaceuticals

analyst at SunTrust

> > > Humphrey, described that development as a

" disaster " for Merck that

has

> > > affected the entire industry.

> > >

> > > Pfizer, the world's largest drug maker,

disappointed investors last

week

> > > with revenues that missed analysts' estimates.

Its profits beat

> estimates

> > by

> > > a penny per share, but it also warned that next

year's results could

be

> > hurt

> > > by the arrival of generic competitors against

four of its drugs.

> > > GlaxoKline, which reports earnings

Thursday, faces several

cheaper

> > > copycat medications that will compete with its

compounds.

> > >

> > > In addition, Hazlett said, pharmaceutical

companies also fear that a

> > victory

> > > by presidential candidate Kerry would lead

to lower drug prices

and

> > > imported drugs from Canada. Kerry has said he

wants government health

> care

> > > programs to negotiate lower prices with drug

companies.

> > >

> > > " The specter of a Democratic administration has

had some effect on the

> > > stocks, " Hazlett said.

> > > Politics aside, Lilly has struggled to keep

sales up and costs down.

> > >

> > > In the past two weeks, Lilly has announced it

would cut 1,000 jobs

from

> > its

> > > work force, which numbers 46,000 worldwide.

Lilly's operations in

> > > Indianapolis will absorb 225. Lilly also

instituted a hiring freeze in

> > > August.

> > >

> > > Those cost-cutting moves helped Lilly post a 6

percent increase in

> profits

> > > in its fiscal third quarter; revenue grew a

modest 4 percent, leaving

> Wall

> > > Street nonplussed.

> > >

> > > " The good news is management had the 'wiggle

room' -- the bad news is

> they

> > > needed it (and likely will continue to), " wrote

Carl Seiden, an

analyst

> > > covering Lilly for the brokerage firm UBS.

> > >

> > > Many analysts are worried by declining sales of

Lilly's blockbuster

> drug,

> > > Zyprexa. It generates more than $4 billion a

year for Lilly, and, by

> some

> > > analysts' estimates, accounts for 60 percent of

the company's profits.

> > >

> > > Sales of the antipsychotic drug fell 9 percent

in Lilly's third

quarter,

> > > including a 22 percent drop in the United

States. And the patent

> challenge

> > > brought against Zyprexa by a generic drug maker,

which is now in the

> hands

> > > of an Indianapolis judge, still hangs like a

cloud over Lilly.

> > >

> > > " We believe investors are better off on the

sidelines until the

> visibility

> > > on the Zyprexa controversies improve, " Seiden

wrote.

> > >

> > > Other analysts have been disappointed in early

sales of Lilly's newest

> > > drugs, such as Strattera, which is used in

treating attention-deficit

> > > hyperactivity disorder.

> > >

> > > But Hazlett takes a rosier view on Lilly. He

points to Cymbalta, an

> > > antidepressant Lilly rolled out this summer, as

evidence for his

> > prediction

> > > of strong profit growth the next two years.

> > >

> > > Hazlett wrote that he " would recommend that

investors use the recent

> > > weakness to establish or add to a position. "

> > >

> > > Star reporter O'Neal contributed to this

story.

> > > Call Star reporter J.K. Wall at (317) 444-6287.

> > >

October 27, 2004

funny, oh come on Jim. lololololol. i'm sorry, but

this is to funny. lololololol Why not????

Connie

--- Jim <mofunnow@...> wrote:

---------------------------------

Nope. Your best bet is to go back to the original post

that I commented on

or

click on the link to the article. What your asking is

that I edit out all

the >'s by hand

and I'm not gonna do it

Best,

Jim

Re: Lilly Stock Spirals

Down (Time for a little

> celebration!)

>

> >

> > I hate for people to lose jobs but I love this

news. goes to show

> > what unethical and harmful products will get a

business everytime.

> > Couldn't happen to a better bunch. Makes me think

carefully about

> > where I will work.

> >

> > >

http://www.indystar.com/articles/3/189440-8983-223.html

> > >

> > > Lilly stock spirals down

> > > The Indianapolis company's share price has hit a

52-week low every day

> > since

> > > Oct. 19.

> > >

> > > By J.K. Wall

> > > jk.wall@...

> > > October 26, 2004

> > >

> > > Eli Lilly and Co. shares hit another 52-week low

Monday as the company

> > > continued to feel the fallout from its own weak

financial growth and

> that

> > of

> > > the whole pharmaceutical industry.

> > >

> > > Shares of the Indianapolis-based company have

fallen nearly 15 percent

> in

> > > the past two weeks, closing Monday at $50.44 a

share. The value has

> fallen

> > > by more than 28 percent since Jan. 1. Lilly

stock closed as high as

> $76.95

> > > in early June.

> > >

> > > The share price has hit a new 52-week low every

day since Oct. 19.

> Lilly,

> > > Central Indiana's largest private employer, last

week announced job

cuts

> > and

> > > reported sales that disappointed Wall Street

analysts.

> > >

> > > If the difficulties at Lilly are prolonged, they

could indirectly

affect

> > the

> > > Lilly Endowment, a massive Indianapolis

philanthropic foundation.

> > >

> > > While the $10.8 billion endowment is independent

of the drug maker,

> Lilly

> > > stock is the endowment's most significant asset.

> > >

> > > For now, however, the company's performance

should not change the

> > > endowment's level of giving, said an official

with the Indiana

> Grantmakers

> > > Alliance.

> > >

> > > " Private foundations are obligated to pay out at

least 5 percent of

> their

> > > assets. However, the 5 percent is based on a

three-year rolling

> average, "

> > > said Audette, vice president of the

alliance, in a written

> > > statement. " Therefore a spike one way or the

other in the market or in

a

> > > particular stock, even if a foundation is heavy

in that stock, has

> little

> > > effect on the long-term giving. "

> > > Other drug companies also aren't faring well on

Wall Street.

> > >

> > > Last week was the fifth straight that the

American Stock Exchange

> > > Pharmaceutical Index fell. The slide started

just before Merck & Co

Inc.

> > > announced that it would yank Vioxx, a popular

arthritis drug, from the

> > > market. Hazlett, a pharmaceuticals

analyst at SunTrust

> > > Humphrey, described that development as a

" disaster " for Merck that

has

> > > affected the entire industry.

> > >

> > > Pfizer, the world's largest drug maker,

disappointed investors last

week

> > > with revenues that missed analysts' estimates.

Its profits beat

> estimates

> > by

> > > a penny per share, but it also warned that next

year's results could

be

> > hurt

> > > by the arrival of generic competitors against

four of its drugs.

> > > GlaxoKline, which reports earnings

Thursday, faces several

cheaper

> > > copycat medications that will compete with its

compounds.

> > >

> > > In addition, Hazlett said, pharmaceutical

companies also fear that a

> > victory

> > > by presidential candidate Kerry would lead

to lower drug prices

and

> > > imported drugs from Canada. Kerry has said he

wants government health

> care

> > > programs to negotiate lower prices with drug

companies.

> > >

> > > " The specter of a Democratic administration has

had some effect on the

> > > stocks, " Hazlett said.

> > > Politics aside, Lilly has struggled to keep

sales up and costs down.

> > >

> > > In the past two weeks, Lilly has announced it

would cut 1,000 jobs

from

> > its

> > > work force, which numbers 46,000 worldwide.

Lilly's operations in

> > > Indianapolis will absorb 225. Lilly also

instituted a hiring freeze in

> > > August.

> > >

> > > Those cost-cutting moves helped Lilly post a 6

percent increase in

> profits

> > > in its fiscal third quarter; revenue grew a

modest 4 percent, leaving

> Wall

> > > Street nonplussed.

> > >

> > > " The good news is management had the 'wiggle

room' -- the bad news is

> they

> > > needed it (and likely will continue to), " wrote

Carl Seiden, an

analyst

> > > covering Lilly for the brokerage firm UBS.

> > >

> > > Many analysts are worried by declining sales of

Lilly's blockbuster

> drug,

> > > Zyprexa. It generates more than $4 billion a

year for Lilly, and, by

> some

> > > analysts' estimates, accounts for 60 percent of

the company's profits.

> > >

> > > Sales of the antipsychotic drug fell 9 percent

in Lilly's third

quarter,

> > > including a 22 percent drop in the United

States. And the patent

> challenge

> > > brought against Zyprexa by a generic drug maker,

which is now in the

> hands

> > > of an Indianapolis judge, still hangs like a

cloud over Lilly.

> > >

> > > " We believe investors are better off on the

sidelines until the

> visibility

> > > on the Zyprexa controversies improve, " Seiden

wrote.

> > >

> > > Other analysts have been disappointed in early

sales of Lilly's newest

> > > drugs, such as Strattera, which is used in

treating attention-deficit

> > > hyperactivity disorder.

> > >

> > > But Hazlett takes a rosier view on Lilly. He

points to Cymbalta, an

> > > antidepressant Lilly rolled out this summer, as

evidence for his

> > prediction

> > > of strong profit growth the next two years.

> > >

> > > Hazlett wrote that he " would recommend that

investors use the recent

> > > weakness to establish or add to a position. "

> > >

> > > Star reporter O'Neal contributed to this

story.

> > > Call Star reporter J.K. Wall at (317) 444-6287.

> > >

October 27, 2004

No worries

Re: Lilly Stock Spirals

> > Down (Time for a little

> > > celebration!)

> > >

> > > >

> > > > I hate for people to lose jobs but I love this

> > news. goes to show

> > > > what unethical and harmful products will get a

> > business everytime.

> > > > Couldn't happen to a better bunch. Makes me think

> > carefully about

> > > > where I will work.

> > > >

> > > > >

> > http://www.indystar.com/articles/3/189440-8983-223.html

> > > > >

> > > > > Lilly stock spirals down

> > > > > The Indianapolis company's share price has hit a

> > 52-week low every day

> > > > since

> > > > > Oct. 19.

> > > > >

> > > > > By J.K. Wall

> > > > > jk.wall@...

> > > > > October 26, 2004

> > > > >

> > > > > Eli Lilly and Co. shares hit another 52-week low

> > Monday as the company

> > > > > continued to feel the fallout from its own weak

> > financial growth and

> > > that

> > > > of

> > > > > the whole pharmaceutical industry.

> > > > >

> > > > > Shares of the Indianapolis-based company have

> > fallen nearly 15 percent

> > > in

> > > > > the past two weeks, closing Monday at $50.44 a

> > share. The value has

> > > fallen

> > > > > by more than 28 percent since Jan. 1. Lilly

> > stock closed as high as

> > > $76.95

> > > > > in early June.

> > > > >

> > > > > The share price has hit a new 52-week low every

> > day since Oct. 19.

> > > Lilly,

> > > > > Central Indiana's largest private employer, last

> > week announced job

> > cuts

> > > > and

> > > > > reported sales that disappointed Wall Street

> > analysts.

> > > > >

> > > > > If the difficulties at Lilly are prolonged, they

> > could indirectly

> > affect

> > > > the

> > > > > Lilly Endowment, a massive Indianapolis

> > philanthropic foundation.

> > > > >

> > > > > While the $10.8 billion endowment is independent

> > of the drug maker,

> > > Lilly

> > > > > stock is the endowment's most significant asset.

> > > > >

> > > > > For now, however, the company's performance

> > should not change the

> > > > > endowment's level of giving, said an official

> > with the Indiana

> > > Grantmakers

> > > > > Alliance.

> > > > >

> > > > > " Private foundations are obligated to pay out at

> > least 5 percent of

> > > their

> > > > > assets. However, the 5 percent is based on a

> > three-year rolling

> > > average, "

> > > > > said Audette, vice president of the

> > alliance, in a written

> > > > > statement. " Therefore a spike one way or the

> > other in the market or in

> > a

> > > > > particular stock, even if a foundation is heavy

> > in that stock, has

> > > little

> > > > > effect on the long-term giving. "

> > > > > Other drug companies also aren't faring well on

> > Wall Street.

> > > > >

> > > > > Last week was the fifth straight that the

> > American Stock Exchange

> > > > > Pharmaceutical Index fell. The slide started

> > just before Merck & Co

> > Inc.

> > > > > announced that it would yank Vioxx, a popular

> > arthritis drug, from the

> > > > > market. Hazlett, a pharmaceuticals

> > analyst at SunTrust

> > > > > Humphrey, described that development as a

> > " disaster " for Merck that

> > has

> > > > > affected the entire industry.

> > > > >

> > > > > Pfizer, the world's largest drug maker,

> > disappointed investors last

> > week

> > > > > with revenues that missed analysts' estimates.

> > Its profits beat

> > > estimates

> > > > by

> > > > > a penny per share, but it also warned that next

> > year's results could

> > be

> > > > hurt

> > > > > by the arrival of generic competitors against

> > four of its drugs.

> > > > > GlaxoKline, which reports earnings

> > Thursday, faces several

> > cheaper

> > > > > copycat medications that will compete with its

> > compounds.

> > > > >

> > > > > In addition, Hazlett said, pharmaceutical

> > companies also fear that a

> > > > victory

> > > > > by presidential candidate Kerry would lead

> > to lower drug prices

> > and

> > > > > imported drugs from Canada. Kerry has said he

> > wants government health

> > > care

> > > > > programs to negotiate lower prices with drug

> > companies.

> > > > >

> > > > > " The specter of a Democratic administration has

> > had some effect on the

> > > > > stocks, " Hazlett said.

> > > > > Politics aside, Lilly has struggled to keep

> > sales up and costs down.

> > > > >

> > > > > In the past two weeks, Lilly has announced it

> > would cut 1,000 jobs

> > from

> > > > its

> > > > > work force, which numbers 46,000 worldwide.

> > Lilly's operations in

> > > > > Indianapolis will absorb 225. Lilly also

> > instituted a hiring freeze in

> > > > > August.

> > > > >

> > > > > Those cost-cutting moves helped Lilly post a 6

> > percent increase in

> > > profits

> > > > > in its fiscal third quarter; revenue grew a

> > modest 4 percent, leaving

> > > Wall

> > > > > Street nonplussed.

> > > > >

> > > > > " The good news is management had the 'wiggle

> > room' -- the bad news is

> > > they

> > > > > needed it (and likely will continue to), " wrote

> > Carl Seiden, an

> > analyst

> > > > > covering Lilly for the brokerage firm UBS.

> > > > >

> > > > > Many analysts are worried by declining sales of

> > Lilly's blockbuster

> > > drug,

> > > > > Zyprexa. It generates more than $4 billion a

> > year for Lilly, and, by

> > > some

> > > > > analysts' estimates, accounts for 60 percent of

> > the company's profits.

> > > > >

> > > > > Sales of the antipsychotic drug fell 9 percent

> > in Lilly's third

> > quarter,

> > > > > including a 22 percent drop in the United

> > States. And the patent

> > > challenge

> > > > > brought against Zyprexa by a generic drug maker,

> > which is now in the

> > > hands

> > > > > of an Indianapolis judge, still hangs like a

> > cloud over Lilly.

> > > > >

> > > > > " We believe investors are better off on the

> > sidelines until the

> > > visibility

> > > > > on the Zyprexa controversies improve, " Seiden

> > wrote.

> > > > >

> > > > > Other analysts have been disappointed in early

> > sales of Lilly's newest

> > > > > drugs, such as Strattera, which is used in

> > treating attention-deficit

> > > > > hyperactivity disorder.

> > > > >

> > > > > But Hazlett takes a rosier view on Lilly. He

> > points to Cymbalta, an

> > > > > antidepressant Lilly rolled out this summer, as

> > evidence for his

> > > > prediction

> > > > > of strong profit growth the next two years.

> > > > >

> > > > > Hazlett wrote that he " would recommend that

> > investors use the recent

> > > > > weakness to establish or add to a position. "

> > > > >

> > > > > Star reporter O'Neal contributed to this

> > story.

> > > > > Call Star reporter J.K. Wall at (317) 444-6287.

> > > > >

October 27, 2004

No worries

Re: Lilly Stock Spirals

> > Down (Time for a little

> > > celebration!)

> > >

> > > >

> > > > I hate for people to lose jobs but I love this

> > news. goes to show

> > > > what unethical and harmful products will get a

> > business everytime.

> > > > Couldn't happen to a better bunch. Makes me think

> > carefully about

> > > > where I will work.

> > > >

> > > > >

> > http://www.indystar.com/articles/3/189440-8983-223.html

> > > > >

> > > > > Lilly stock spirals down

> > > > > The Indianapolis company's share price has hit a

> > 52-week low every day

> > > > since

> > > > > Oct. 19.

> > > > >

> > > > > By J.K. Wall

> > > > > jk.wall@...

> > > > > October 26, 2004

> > > > >

> > > > > Eli Lilly and Co. shares hit another 52-week low

> > Monday as the company

> > > > > continued to feel the fallout from its own weak

> > financial growth and

> > > that

> > > > of

> > > > > the whole pharmaceutical industry.

> > > > >

> > > > > Shares of the Indianapolis-based company have

> > fallen nearly 15 percent

> > > in

> > > > > the past two weeks, closing Monday at $50.44 a

> > share. The value has

> > > fallen

> > > > > by more than 28 percent since Jan. 1. Lilly

> > stock closed as high as

> > > $76.95

> > > > > in early June.

> > > > >

> > > > > The share price has hit a new 52-week low every

> > day since Oct. 19.

> > > Lilly,

> > > > > Central Indiana's largest private employer, last

> > week announced job

> > cuts

> > > > and

> > > > > reported sales that disappointed Wall Street

> > analysts.

> > > > >

> > > > > If the difficulties at Lilly are prolonged, they

> > could indirectly

> > affect

> > > > the

> > > > > Lilly Endowment, a massive Indianapolis

> > philanthropic foundation.

> > > > >

> > > > > While the $10.8 billion endowment is independent

> > of the drug maker,

> > > Lilly

> > > > > stock is the endowment's most significant asset.

> > > > >

> > > > > For now, however, the company's performance

> > should not change the

> > > > > endowment's level of giving, said an official

> > with the Indiana

> > > Grantmakers

> > > > > Alliance.

> > > > >

> > > > > " Private foundations are obligated to pay out at

> > least 5 percent of

> > > their

> > > > > assets. However, the 5 percent is based on a

> > three-year rolling

> > > average, "

> > > > > said Audette, vice president of the

> > alliance, in a written

> > > > > statement. " Therefore a spike one way or the

> > other in the market or in

> > a

> > > > > particular stock, even if a foundation is heavy

> > in that stock, has

> > > little

> > > > > effect on the long-term giving. "

> > > > > Other drug companies also aren't faring well on

> > Wall Street.

> > > > >

> > > > > Last week was the fifth straight that the

> > American Stock Exchange

> > > > > Pharmaceutical Index fell. The slide started

> > just before Merck & Co

> > Inc.

> > > > > announced that it would yank Vioxx, a popular

> > arthritis drug, from the

> > > > > market. Hazlett, a pharmaceuticals

> > analyst at SunTrust

> > > > > Humphrey, described that development as a

> > " disaster " for Merck that

> > has

> > > > > affected the entire industry.

> > > > >

> > > > > Pfizer, the world's largest drug maker,

> > disappointed investors last

> > week

> > > > > with revenues that missed analysts' estimates.

> > Its profits beat

> > > estimates

> > > > by

> > > > > a penny per share, but it also warned that next

> > year's results could

> > be

> > > > hurt

> > > > > by the arrival of generic competitors against

> > four of its drugs.

> > > > > GlaxoKline, which reports earnings

> > Thursday, faces several

> > cheaper

> > > > > copycat medications that will compete with its

> > compounds.

> > > > >

> > > > > In addition, Hazlett said, pharmaceutical

> > companies also fear that a

> > > > victory

> > > > > by presidential candidate Kerry would lead

> > to lower drug prices

> > and

> > > > > imported drugs from Canada. Kerry has said he

> > wants government health

> > > care

> > > > > programs to negotiate lower prices with drug

> > companies.

> > > > >

> > > > > " The specter of a Democratic administration has

> > had some effect on the

> > > > > stocks, " Hazlett said.

> > > > > Politics aside, Lilly has struggled to keep

> > sales up and costs down.

> > > > >

> > > > > In the past two weeks, Lilly has announced it

> > would cut 1,000 jobs

> > from

> > > > its

> > > > > work force, which numbers 46,000 worldwide.

> > Lilly's operations in

> > > > > Indianapolis will absorb 225. Lilly also

> > instituted a hiring freeze in

> > > > > August.

> > > > >

> > > > > Those cost-cutting moves helped Lilly post a 6

> > percent increase in

> > > profits

> > > > > in its fiscal third quarter; revenue grew a

> > modest 4 percent, leaving

> > > Wall

> > > > > Street nonplussed.

> > > > >

> > > > > " The good news is management had the 'wiggle

> > room' -- the bad news is

> > > they

> > > > > needed it (and likely will continue to), " wrote

> > Carl Seiden, an

> > analyst

> > > > > covering Lilly for the brokerage firm UBS.

> > > > >

> > > > > Many analysts are worried by declining sales of

> > Lilly's blockbuster

> > > drug,

> > > > > Zyprexa. It generates more than $4 billion a

> > year for Lilly, and, by

> > > some

> > > > > analysts' estimates, accounts for 60 percent of

> > the company's profits.

> > > > >

> > > > > Sales of the antipsychotic drug fell 9 percent

> > in Lilly's third

> > quarter,

> > > > > including a 22 percent drop in the United

> > States. And the patent

> > > challenge

> > > > > brought against Zyprexa by a generic drug maker,

> > which is now in the

> > > hands

> > > > > of an Indianapolis judge, still hangs like a

> > cloud over Lilly.

> > > > >

> > > > > " We believe investors are better off on the

> > sidelines until the

> > > visibility

> > > > > on the Zyprexa controversies improve, " Seiden

> > wrote.

> > > > >

> > > > > Other analysts have been disappointed in early

> > sales of Lilly's newest

> > > > > drugs, such as Strattera, which is used in

> > treating attention-deficit

> > > > > hyperactivity disorder.

> > > > >

> > > > > But Hazlett takes a rosier view on Lilly. He

> > points to Cymbalta, an

> > > > > antidepressant Lilly rolled out this summer, as

> > evidence for his

> > > > prediction

> > > > > of strong profit growth the next two years.

> > > > >

> > > > > Hazlett wrote that he " would recommend that

> > investors use the recent

> > > > > weakness to establish or add to a position. "

> > > > >

> > > > > Star reporter O'Neal contributed to this

> > story.

> > > > > Call Star reporter J.K. Wall at (317) 444-6287.

> > > > >

October 27, 2004

Hey Connie and Dr. Lance,

Heeehehee yeah I feel dumb about it now, at the time it looked like

a pretty silly request considering Cassandra's first post is the one

I was responding to and was twenty emails up.

Also the link is right there, all you need to do is click on it.

Yes even I can get cranky on occasion. It just seemed like a ridiculous

request at the time.

Of course now I feel pretty silly about it myself.

I always try to treat people with the deepest respect and

there I go acting like a complete ass.

Apologies all around and especially to Dr. Lance.

Jim

Re: Lilly Stock Spirals

> Down (Time for a little

> > celebration!)

> >

> > >

> > > I hate for people to lose jobs but I love this

> news. goes to show

> > > what unethical and harmful products will get a

> business everytime.

> > > Couldn't happen to a better bunch. Makes me think

> carefully about

> > > where I will work.

> > >

> > > >

> http://www.indystar.com/articles/3/189440-8983-223.html

> > > >

> > > > Lilly stock spirals down

> > > > The Indianapolis company's share price has hit a

> 52-week low every day

> > > since

> > > > Oct. 19.

> > > >

> > > > By J.K. Wall

> > > > jk.wall@...

> > > > October 26, 2004

> > > >

> > > > Eli Lilly and Co. shares hit another 52-week low

> Monday as the company

> > > > continued to feel the fallout from its own weak

> financial growth and

> > that

> > > of

> > > > the whole pharmaceutical industry.

> > > >

> > > > Shares of the Indianapolis-based company have

> fallen nearly 15 percent

> > in

> > > > the past two weeks, closing Monday at $50.44 a

> share. The value has

> > fallen

> > > > by more than 28 percent since Jan. 1. Lilly

> stock closed as high as

> > $76.95

> > > > in early June.

> > > >

> > > > The share price has hit a new 52-week low every

> day since Oct. 19.

> > Lilly,

> > > > Central Indiana's largest private employer, last

> week announced job

> cuts

> > > and

> > > > reported sales that disappointed Wall Street

> analysts.

> > > >

> > > > If the difficulties at Lilly are prolonged, they

> could indirectly

> affect

> > > the

> > > > Lilly Endowment, a massive Indianapolis

> philanthropic foundation.

> > > >

> > > > While the $10.8 billion endowment is independent

> of the drug maker,

> > Lilly

> > > > stock is the endowment's most significant asset.

> > > >

> > > > For now, however, the company's performance

> should not change the

> > > > endowment's level of giving, said an official

> with the Indiana

> > Grantmakers

> > > > Alliance.

> > > >

> > > > " Private foundations are obligated to pay out at

> least 5 percent of

> > their

> > > > assets. However, the 5 percent is based on a

> three-year rolling

> > average, "

> > > > said Audette, vice president of the

> alliance, in a written

> > > > statement. " Therefore a spike one way or the

> other in the market or in

> a

> > > > particular stock, even if a foundation is heavy

> in that stock, has

> > little

> > > > effect on the long-term giving. "

> > > > Other drug companies also aren't faring well on

> Wall Street.

> > > >

> > > > Last week was the fifth straight that the

> American Stock Exchange

> > > > Pharmaceutical Index fell. The slide started

> just before Merck & Co

> Inc.

> > > > announced that it would yank Vioxx, a popular

> arthritis drug, from the

> > > > market. Hazlett, a pharmaceuticals

> analyst at SunTrust

> > > > Humphrey, described that development as a

> " disaster " for Merck that

> has

> > > > affected the entire industry.

> > > >

> > > > Pfizer, the world's largest drug maker,

> disappointed investors last

> week

> > > > with revenues that missed analysts' estimates.

> Its profits beat

> > estimates

> > > by

> > > > a penny per share, but it also warned that next

> year's results could

> be

> > > hurt

> > > > by the arrival of generic competitors against

> four of its drugs.

> > > > GlaxoKline, which reports earnings

> Thursday, faces several

> cheaper

> > > > copycat medications that will compete with its

> compounds.

> > > >

> > > > In addition, Hazlett said, pharmaceutical

> companies also fear that a

> > > victory

> > > > by presidential candidate Kerry would lead

> to lower drug prices

> and

> > > > imported drugs from Canada. Kerry has said he

> wants government health

> > care

> > > > programs to negotiate lower prices with drug

> companies.

> > > >

> > > > " The specter of a Democratic administration has

> had some effect on the

> > > > stocks, " Hazlett said.

> > > > Politics aside, Lilly has struggled to keep

> sales up and costs down.

> > > >

> > > > In the past two weeks, Lilly has announced it

> would cut 1,000 jobs

> from

> > > its

> > > > work force, which numbers 46,000 worldwide.

> Lilly's operations in

> > > > Indianapolis will absorb 225. Lilly also

> instituted a hiring freeze in

> > > > August.

> > > >

> > > > Those cost-cutting moves helped Lilly post a 6

> percent increase in

> > profits

> > > > in its fiscal third quarter; revenue grew a

> modest 4 percent, leaving

> > Wall

> > > > Street nonplussed.

> > > >

> > > > " The good news is management had the 'wiggle

> room' -- the bad news is

> > they

> > > > needed it (and likely will continue to), " wrote

> Carl Seiden, an

> analyst

> > > > covering Lilly for the brokerage firm UBS.

> > > >

> > > > Many analysts are worried by declining sales of

> Lilly's blockbuster

> > drug,

> > > > Zyprexa. It generates more than $4 billion a

> year for Lilly, and, by

> > some

> > > > analysts' estimates, accounts for 60 percent of

> the company's profits.

> > > >

> > > > Sales of the antipsychotic drug fell 9 percent

> in Lilly's third

> quarter,

> > > > including a 22 percent drop in the United

> States. And the patent

> > challenge

> > > > brought against Zyprexa by a generic drug maker,

> which is now in the

> > hands

> > > > of an Indianapolis judge, still hangs like a

> cloud over Lilly.

> > > >

> > > > " We believe investors are better off on the

> sidelines until the

> > visibility

> > > > on the Zyprexa controversies improve, " Seiden

> wrote.

> > > >

> > > > Other analysts have been disappointed in early

> sales of Lilly's newest

> > > > drugs, such as Strattera, which is used in

> treating attention-deficit

> > > > hyperactivity disorder.

> > > >

> > > > But Hazlett takes a rosier view on Lilly. He

> points to Cymbalta, an

> > > > antidepressant Lilly rolled out this summer, as

> evidence for his

> > > prediction

> > > > of strong profit growth the next two years.

> > > >

> > > > Hazlett wrote that he " would recommend that

> investors use the recent

> > > > weakness to establish or add to a position. "

> > > >

> > > > Star reporter O'Neal contributed to this

> story.

> > > > Call Star reporter J.K. Wall at (317) 444-6287.

> > > >

October 27, 2004

Hey Connie and Dr. Lance,

Heeehehee yeah I feel dumb about it now, at the time it looked like

a pretty silly request considering Cassandra's first post is the one

I was responding to and was twenty emails up.

Also the link is right there, all you need to do is click on it.

Yes even I can get cranky on occasion. It just seemed like a ridiculous

request at the time.

Of course now I feel pretty silly about it myself.

I always try to treat people with the deepest respect and

there I go acting like a complete ass.

Apologies all around and especially to Dr. Lance.

Jim

Re: Lilly Stock Spirals

> Down (Time for a little

> > celebration!)

> >

> > >

> > > I hate for people to lose jobs but I love this

> news. goes to show

> > > what unethical and harmful products will get a

> business everytime.

> > > Couldn't happen to a better bunch. Makes me think

> carefully about

> > > where I will work.

> > >

> > > >

> http://www.indystar.com/articles/3/189440-8983-223.html

> > > >

> > > > Lilly stock spirals down

> > > > The Indianapolis company's share price has hit a

> 52-week low every day

> > > since

> > > > Oct. 19.

> > > >

> > > > By J.K. Wall

> > > > jk.wall@...

> > > > October 26, 2004

> > > >

> > > > Eli Lilly and Co. shares hit another 52-week low

> Monday as the company

> > > > continued to feel the fallout from its own weak

> financial growth and

> > that

> > > of

> > > > the whole pharmaceutical industry.

> > > >

> > > > Shares of the Indianapolis-based company have

> fallen nearly 15 percent

> > in

> > > > the past two weeks, closing Monday at $50.44 a

> share. The value has

> > fallen

> > > > by more than 28 percent since Jan. 1. Lilly

> stock closed as high as

> > $76.95

> > > > in early June.

> > > >

> > > > The share price has hit a new 52-week low every

> day since Oct. 19.

> > Lilly,

> > > > Central Indiana's largest private employer, last

> week announced job

> cuts

> > > and

> > > > reported sales that disappointed Wall Street

> analysts.

> > > >

> > > > If the difficulties at Lilly are prolonged, they

> could indirectly

> affect

> > > the

> > > > Lilly Endowment, a massive Indianapolis

> philanthropic foundation.

> > > >

> > > > While the $10.8 billion endowment is independent

> of the drug maker,

> > Lilly

> > > > stock is the endowment's most significant asset.

> > > >

> > > > For now, however, the company's performance

> should not change the

> > > > endowment's level of giving, said an official

> with the Indiana

> > Grantmakers

> > > > Alliance.

> > > >

> > > > " Private foundations are obligated to pay out at

> least 5 percent of

> > their

> > > > assets. However, the 5 percent is based on a

> three-year rolling

> > average, "

> > > > said Audette, vice president of the

> alliance, in a written

> > > > statement. " Therefore a spike one way or the

> other in the market or in

> a

> > > > particular stock, even if a foundation is heavy

> in that stock, has

> > little

> > > > effect on the long-term giving. "

> > > > Other drug companies also aren't faring well on

> Wall Street.

> > > >

> > > > Last week was the fifth straight that the

> American Stock Exchange

> > > > Pharmaceutical Index fell. The slide started

> just before Merck & Co

> Inc.

> > > > announced that it would yank Vioxx, a popular

> arthritis drug, from the

> > > > market. Hazlett, a pharmaceuticals

> analyst at SunTrust

> > > > Humphrey, described that development as a

> " disaster " for Merck that

> has

> > > > affected the entire industry.

> > > >

> > > > Pfizer, the world's largest drug maker,

> disappointed investors last

> week

> > > > with revenues that missed analysts' estimates.

> Its profits beat

> > estimates

> > > by

> > > > a penny per share, but it also warned that next

> year's results could

> be

> > > hurt

> > > > by the arrival of generic competitors against

> four of its drugs.

> > > > GlaxoKline, which reports earnings

> Thursday, faces several

> cheaper

> > > > copycat medications that will compete with its

> compounds.

> > > >

> > > > In addition, Hazlett said, pharmaceutical

> companies also fear that a

> > > victory

> > > > by presidential candidate Kerry would lead

> to lower drug prices

> and

> > > > imported drugs from Canada. Kerry has said he

> wants government health

> > care

> > > > programs to negotiate lower prices with drug

> companies.

> > > >

> > > > " The specter of a Democratic administration has

> had some effect on the

> > > > stocks, " Hazlett said.

> > > > Politics aside, Lilly has struggled to keep

> sales up and costs down.

> > > >

> > > > In the past two weeks, Lilly has announced it

> would cut 1,000 jobs

> from

> > > its

> > > > work force, which numbers 46,000 worldwide.

> Lilly's operations in

> > > > Indianapolis will absorb 225. Lilly also

> instituted a hiring freeze in

> > > > August.

> > > >

> > > > Those cost-cutting moves helped Lilly post a 6

> percent increase in

> > profits

> > > > in its fiscal third quarter; revenue grew a

> modest 4 percent, leaving

> > Wall

> > > > Street nonplussed.

> > > >

> > > > " The good news is management had the 'wiggle

> room' -- the bad news is

> > they

> > > > needed it (and likely will continue to), " wrote

> Carl Seiden, an

> analyst

> > > > covering Lilly for the brokerage firm UBS.

> > > >

> > > > Many analysts are worried by declining sales of

> Lilly's blockbuster

> > drug,

> > > > Zyprexa. It generates more than $4 billion a

> year for Lilly, and, by

> > some

> > > > analysts' estimates, accounts for 60 percent of

> the company's profits.

> > > >

> > > > Sales of the antipsychotic drug fell 9 percent

> in Lilly's third

> quarter,

> > > > including a 22 percent drop in the United

> States. And the patent

> > challenge

> > > > brought against Zyprexa by a generic drug maker,

> which is now in the

> > hands

> > > > of an Indianapolis judge, still hangs like a

> cloud over Lilly.

> > > >

> > > > " We believe investors are better off on the

> sidelines until the

> > visibility

> > > > on the Zyprexa controversies improve, " Seiden

> wrote.

> > > >

> > > > Other analysts have been disappointed in early

> sales of Lilly's newest

> > > > drugs, such as Strattera, which is used in

> treating attention-deficit

> > > > hyperactivity disorder.

> > > >

> > > > But Hazlett takes a rosier view on Lilly. He

> points to Cymbalta, an

> > > > antidepressant Lilly rolled out this summer, as

> evidence for his

> > > prediction

> > > > of strong profit growth the next two years.

> > > >

> > > > Hazlett wrote that he " would recommend that

> investors use the recent

> > > > weakness to establish or add to a position. "

> > > >

> > > > Star reporter O'Neal contributed to this

> story.

> > > > Call Star reporter J.K. Wall at (317) 444-6287.

> > > >

October 27, 2004

Hey Connie and Dr. Lance,

Heeehehee yeah I feel dumb about it now, at the time it looked like

a pretty silly request considering Cassandra's first post is the one

I was responding to and was twenty emails up.

Also the link is right there, all you need to do is click on it.

Yes even I can get cranky on occasion. It just seemed like a ridiculous

request at the time.

Of course now I feel pretty silly about it myself.

I always try to treat people with the deepest respect and

there I go acting like a complete ass.

Apologies all around and especially to Dr. Lance.

Jim

Re: Lilly Stock Spirals

> Down (Time for a little

> > celebration!)

> >

> > >

> > > I hate for people to lose jobs but I love this

> news. goes to show

> > > what unethical and harmful products will get a

> business everytime.

> > > Couldn't happen to a better bunch. Makes me think

> carefully about

> > > where I will work.

> > >

> > > >

> http://www.indystar.com/articles/3/189440-8983-223.html

> > > >

> > > > Lilly stock spirals down

> > > > The Indianapolis company's share price has hit a

> 52-week low every day

> > > since

> > > > Oct. 19.

> > > >

> > > > By J.K. Wall

> > > > jk.wall@...

> > > > October 26, 2004

> > > >

> > > > Eli Lilly and Co. shares hit another 52-week low

> Monday as the company

> > > > continued to feel the fallout from its own weak

> financial growth and

> > that

> > > of

> > > > the whole pharmaceutical industry.

> > > >

> > > > Shares of the Indianapolis-based company have

> fallen nearly 15 percent

> > in

> > > > the past two weeks, closing Monday at $50.44 a

> share. The value has

> > fallen

> > > > by more than 28 percent since Jan. 1. Lilly

> stock closed as high as

> > $76.95

> > > > in early June.

> > > >

> > > > The share price has hit a new 52-week low every

> day since Oct. 19.

> > Lilly,

> > > > Central Indiana's largest private employer, last

> week announced job

> cuts

> > > and

> > > > reported sales that disappointed Wall Street

> analysts.

> > > >

> > > > If the difficulties at Lilly are prolonged, they

> could indirectly

> affect

> > > the

> > > > Lilly Endowment, a massive Indianapolis

> philanthropic foundation.

> > > >

> > > > While the $10.8 billion endowment is independent

> of the drug maker,

> > Lilly

> > > > stock is the endowment's most significant asset.

> > > >

> > > > For now, however, the company's performance

> should not change the

> > > > endowment's level of giving, said an official

> with the Indiana

> > Grantmakers

> > > > Alliance.

> > > >

> > > > " Private foundations are obligated to pay out at

> least 5 percent of

> > their

> > > > assets. However, the 5 percent is based on a

> three-year rolling

> > average, "

> > > > said Audette, vice president of the

> alliance, in a written

> > > > statement. " Therefore a spike one way or the

> other in the market or in

> a

> > > > particular stock, even if a foundation is heavy

> in that stock, has

> > little

> > > > effect on the long-term giving. "

> > > > Other drug companies also aren't faring well on

> Wall Street.

> > > >

> > > > Last week was the fifth straight that the

> American Stock Exchange

> > > > Pharmaceutical Index fell. The slide started

> just before Merck & Co

> Inc.

> > > > announced that it would yank Vioxx, a popular

> arthritis drug, from the

> > > > market. Hazlett, a pharmaceuticals

> analyst at SunTrust

> > > > Humphrey, described that development as a

> " disaster " for Merck that

> has

> > > > affected the entire industry.

> > > >

> > > > Pfizer, the world's largest drug maker,

> disappointed investors last

> week

> > > > with revenues that missed analysts' estimates.

> Its profits beat

> > estimates

> > > by

> > > > a penny per share, but it also warned that next

> year's results could

> be

> > > hurt

> > > > by the arrival of generic competitors against

> four of its drugs.

> > > > GlaxoKline, which reports earnings

> Thursday, faces several

> cheaper

> > > > copycat medications that will compete with its

> compounds.

> > > >

> > > > In addition, Hazlett said, pharmaceutical

> companies also fear that a

> > > victory

> > > > by presidential candidate Kerry would lead

> to lower drug prices

> and

> > > > imported drugs from Canada. Kerry has said he

> wants government health

> > care

> > > > programs to negotiate lower prices with drug

> companies.

> > > >

> > > > " The specter of a Democratic administration has

> had some effect on the

> > > > stocks, " Hazlett said.

> > > > Politics aside, Lilly has struggled to keep

> sales up and costs down.

> > > >

> > > > In the past two weeks, Lilly has announced it

> would cut 1,000 jobs

> from

> > > its

> > > > work force, which numbers 46,000 worldwide.

> Lilly's operations in

> > > > Indianapolis will absorb 225. Lilly also

> instituted a hiring freeze in

> > > > August.

> > > >

> > > > Those cost-cutting moves helped Lilly post a 6

> percent increase in

> > profits

> > > > in its fiscal third quarter; revenue grew a

> modest 4 percent, leaving

> > Wall

> > > > Street nonplussed.

> > > >

> > > > " The good news is management had the 'wiggle

> room' -- the bad news is

> > they

> > > > needed it (and likely will continue to), " wrote

> Carl Seiden, an

> analyst

> > > > covering Lilly for the brokerage firm UBS.

> > > >

> > > > Many analysts are worried by declining sales of

> Lilly's blockbuster

> > drug,

> > > > Zyprexa. It generates more than $4 billion a

> year for Lilly, and, by

> > some

> > > > analysts' estimates, accounts for 60 percent of

> the company's profits.

> > > >

> > > > Sales of the antipsychotic drug fell 9 percent

> in Lilly's third

> quarter,

> > > > including a 22 percent drop in the United

> States. And the patent

> > challenge

> > > > brought against Zyprexa by a generic drug maker,

> which is now in the

> > hands

> > > > of an Indianapolis judge, still hangs like a

> cloud over Lilly.

> > > >

> > > > " We believe investors are better off on the

> sidelines until the

> > visibility

> > > > on the Zyprexa controversies improve, " Seiden

> wrote.

> > > >

> > > > Other analysts have been disappointed in early

> sales of Lilly's newest

> > > > drugs, such as Strattera, which is used in

> treating attention-deficit

> > > > hyperactivity disorder.

> > > >

> > > > But Hazlett takes a rosier view on Lilly. He

> points to Cymbalta, an

> > > > antidepressant Lilly rolled out this summer, as

> evidence for his

> > > prediction

> > > > of strong profit growth the next two years.

> > > >

> > > > Hazlett wrote that he " would recommend that

> investors use the recent

> > > > weakness to establish or add to a position. "

> > > >

> > > > Star reporter O'Neal contributed to this

> story.

> > > > Call Star reporter J.K. Wall at (317) 444-6287.

> > > >

October 27, 2004

Hey Connie and Dr. Lance,

Heeehehee yeah I feel dumb about it now, at the time it looked like

a pretty silly request considering Cassandra's first post is the one

I was responding to and was twenty emails up.

Also the link is right there, all you need to do is click on it.

Yes even I can get cranky on occasion. It just seemed like a ridiculous

request at the time.

Of course now I feel pretty silly about it myself.

I always try to treat people with the deepest respect and

there I go acting like a complete ass.

Apologies all around and especially to Dr. Lance.

Jim

Re: Lilly Stock Spirals

> Down (Time for a little

> > celebration!)

> >

> > >

> > > I hate for people to lose jobs but I love this

> news. goes to show

> > > what unethical and harmful products will get a

> business everytime.

> > > Couldn't happen to a better bunch. Makes me think

> carefully about

> > > where I will work.

> > >

> > > >

> http://www.indystar.com/articles/3/189440-8983-223.html

> > > >

> > > > Lilly stock spirals down

> > > > The Indianapolis company's share price has hit a

> 52-week low every day

> > > since

> > > > Oct. 19.

> > > >

> > > > By J.K. Wall

> > > > jk.wall@...

> > > > October 26, 2004

> > > >

> > > > Eli Lilly and Co. shares hit another 52-week low

> Monday as the company

> > > > continued to feel the fallout from its own weak

> financial growth and

> > that

> > > of

> > > > the whole pharmaceutical industry.

> > > >

> > > > Shares of the Indianapolis-based company have

> fallen nearly 15 percent

> > in

> > > > the past two weeks, closing Monday at $50.44 a

> share. The value has

> > fallen

> > > > by more than 28 percent since Jan. 1. Lilly

> stock closed as high as

> > $76.95

> > > > in early June.

> > > >

> > > > The share price has hit a new 52-week low every

> day since Oct. 19.

> > Lilly,

> > > > Central Indiana's largest private employer, last

> week announced job

> cuts

> > > and

> > > > reported sales that disappointed Wall Street

> analysts.

> > > >

> > > > If the difficulties at Lilly are prolonged, they

> could indirectly

> affect

> > > the

> > > > Lilly Endowment, a massive Indianapolis

> philanthropic foundation.

> > > >

> > > > While the $10.8 billion endowment is independent

> of the drug maker,

> > Lilly

> > > > stock is the endowment's most significant asset.

> > > >

> > > > For now, however, the company's performance

> should not change the

> > > > endowment's level of giving, said an official

> with the Indiana

> > Grantmakers

> > > > Alliance.

> > > >

> > > > " Private foundations are obligated to pay out at

> least 5 percent of

> > their

> > > > assets. However, the 5 percent is based on a

> three-year rolling

> > average, "

> > > > said Audette, vice president of the

> alliance, in a written

> > > > statement. " Therefore a spike one way or the

> other in the market or in

> a

> > > > particular stock, even if a foundation is heavy

> in that stock, has

> > little

> > > > effect on the long-term giving. "

> > > > Other drug companies also aren't faring well on

> Wall Street.

> > > >

> > > > Last week was the fifth straight that the

> American Stock Exchange

> > > > Pharmaceutical Index fell. The slide started

> just before Merck & Co

> Inc.

> > > > announced that it would yank Vioxx, a popular

> arthritis drug, from the

> > > > market. Hazlett, a pharmaceuticals

> analyst at SunTrust

> > > > Humphrey, described that development as a

> " disaster " for Merck that

> has

> > > > affected the entire industry.

> > > >

> > > > Pfizer, the world's largest drug maker,

> disappointed investors last

> week

> > > > with revenues that missed analysts' estimates.

> Its profits beat

> > estimates

> > > by

> > > > a penny per share, but it also warned that next

> year's results could

> be

> > > hurt

> > > > by the arrival of generic competitors against

> four of its drugs.

> > > > GlaxoKline, which reports earnings

> Thursday, faces several

> cheaper

> > > > copycat medications that will compete with its

> compounds.

> > > >

> > > > In addition, Hazlett said, pharmaceutical

> companies also fear that a

> > > victory

> > > > by presidential candidate Kerry would lead

> to lower drug prices

> and

> > > > imported drugs from Canada. Kerry has said he

> wants government health

> > care

> > > > programs to negotiate lower prices with drug

> companies.

> > > >

> > > > " The specter of a Democratic administration has

> had some effect on the

> > > > stocks, " Hazlett said.

> > > > Politics aside, Lilly has struggled to keep

> sales up and costs down.

> > > >

> > > > In the past two weeks, Lilly has announced it

> would cut 1,000 jobs

> from

> > > its

> > > > work force, which numbers 46,000 worldwide.

> Lilly's operations in

> > > > Indianapolis will absorb 225. Lilly also

> instituted a hiring freeze in

> > > > August.

> > > >

> > > > Those cost-cutting moves helped Lilly post a 6

> percent increase in

> > profits

> > > > in its fiscal third quarter; revenue grew a

> modest 4 percent, leaving

> > Wall

> > > > Street nonplussed.

> > > >

> > > > " The good news is management had the 'wiggle

> room' -- the bad news is

> > they

> > > > needed it (and likely will continue to), " wrote

> Carl Seiden, an

> analyst

> > > > covering Lilly for the brokerage firm UBS.

> > > >

> > > > Many analysts are worried by declining sales of

> Lilly's blockbuster

> > drug,

> > > > Zyprexa. It generates more than $4 billion a

> year for Lilly, and, by

> > some

> > > > analysts' estimates, accounts for 60 percent of

> the company's profits.

> > > >

> > > > Sales of the antipsychotic drug fell 9 percent

> in Lilly's third

> quarter,

> > > > including a 22 percent drop in the United

> States. And the patent

> > challenge

> > > > brought against Zyprexa by a generic drug maker,

> which is now in the

> > hands

> > > > of an Indianapolis judge, still hangs like a

> cloud over Lilly.

> > > >

> > > > " We believe investors are better off on the

> sidelines until the

> > visibility

> > > > on the Zyprexa controversies improve, " Seiden

> wrote.

> > > >

> > > > Other analysts have been disappointed in early

> sales of Lilly's newest

> > > > drugs, such as Strattera, which is used in

> treating attention-deficit

> > > > hyperactivity disorder.

> > > >

> > > > But Hazlett takes a rosier view on Lilly. He

> points to Cymbalta, an

> > > > antidepressant Lilly rolled out this summer, as

> evidence for his

> > > prediction

> > > > of strong profit growth the next two years.

> > > >

> > > > Hazlett wrote that he " would recommend that

> investors use the recent

> > > > weakness to establish or add to a position. "

> > > >

> > > > Star reporter O'Neal contributed to this

> story.

> > > > Call Star reporter J.K. Wall at (317) 444-6287.

> > > >

October 27, 2004

Jim,

You're a little edge/

Haev a little anxiety?

Don'tn get along well with others?

Do you have whatever that syndrome they've named up to call people who have

the normal feeling of feeling uncomfortable going into a room of people?

Perhaps you need to try a litttle

zoloft

or diospen

depakote

seroquel

paxil

lithium

effexor

let's see I'm sure there's a couple they experimended on with myh Mother

that i've forgotten

try a few of those if you're cranky

they'll fix you right up.

Re: Lilly Stock Spirals

> > Down (Time for a little

> > > celebration!)

> > >

> > > >

> > > > I hate for people to lose jobs but I love this

> > news. goes to show

> > > > what unethical and harmful products will get a

> > business everytime.

> > > > Couldn't happen to a better bunch. Makes me think

> > carefully about

> > > > where I will work.

> > > >

> > > > >

> > http://www.indystar.com/articles/3/189440-8983-223.html

> > > > >

> > > > > Lilly stock spirals down

> > > > > The Indianapolis company's share price has hit a

> > 52-week low every day

> > > > since

> > > > > Oct. 19.

> > > > >

> > > > > By J.K. Wall

> > > > > jk.wall@...

> > > > > October 26, 2004

> > > > >

> > > > > Eli Lilly and Co. shares hit another 52-week low

> > Monday as the company

> > > > > continued to feel the fallout from its own weak

> > financial growth and

> > > that

> > > > of

> > > > > the whole pharmaceutical industry.

> > > > >

> > > > > Shares of the Indianapolis-based company have

> > fallen nearly 15 percent

> > > in

> > > > > the past two weeks, closing Monday at $50.44 a

> > share. The value has

> > > fallen

> > > > > by more than 28 percent since Jan. 1. Lilly

> > stock closed as high as

> > > $76.95

> > > > > in early June.

> > > > >

> > > > > The share price has hit a new 52-week low every

> > day since Oct. 19.

> > > Lilly,

> > > > > Central Indiana's largest private employer, last

> > week announced job

> > cuts

> > > > and

> > > > > reported sales that disappointed Wall Street

> > analysts.

> > > > >

> > > > > If the difficulties at Lilly are prolonged, they

> > could indirectly

> > affect

> > > > the

> > > > > Lilly Endowment, a massive Indianapolis

> > philanthropic foundation.

> > > > >

> > > > > While the $10.8 billion endowment is independent

> > of the drug maker,

> > > Lilly

> > > > > stock is the endowment's most significant asset.

> > > > >

> > > > > For now, however, the company's performance

> > should not change the

> > > > > endowment's level of giving, said an official

> > with the Indiana

> > > Grantmakers

> > > > > Alliance.

> > > > >

> > > > > " Private foundations are obligated to pay out at

> > least 5 percent of

> > > their

> > > > > assets. However, the 5 percent is based on a

> > three-year rolling

> > > average, "

> > > > > said Audette, vice president of the

> > alliance, in a written

> > > > > statement. " Therefore a spike one way or the

> > other in the market or in

> > a

> > > > > particular stock, even if a foundation is heavy

> > in that stock, has

> > > little

> > > > > effect on the long-term giving. "

> > > > > Other drug companies also aren't faring well on

> > Wall Street.

> > > > >

> > > > > Last week was the fifth straight that the

> > American Stock Exchange

> > > > > Pharmaceutical Index fell. The slide started

> > just before Merck & Co

> > Inc.

> > > > > announced that it would yank Vioxx, a popular

> > arthritis drug, from the

> > > > > market. Hazlett, a pharmaceuticals

> > analyst at SunTrust

> > > > > Humphrey, described that development as a

> > " disaster " for Merck that

> > has

> > > > > affected the entire industry.

> > > > >

> > > > > Pfizer, the world's largest drug maker,

> > disappointed investors last

> > week

> > > > > with revenues that missed analysts' estimates.

> > Its profits beat

> > > estimates

> > > > by

> > > > > a penny per share, but it also warned that next

> > year's results could

> > be

> > > > hurt

> > > > > by the arrival of generic competitors against

> > four of its drugs.

> > > > > GlaxoKline, which reports earnings

> > Thursday, faces several

> > cheaper

> > > > > copycat medications that will compete with its

> > compounds.

> > > > >

> > > > > In addition, Hazlett said, pharmaceutical

> > companies also fear that a

> > > > victory

> > > > > by presidential candidate Kerry would lead

> > to lower drug prices

> > and

> > > > > imported drugs from Canada. Kerry has said he

> > wants government health

> > > care

> > > > > programs to negotiate lower prices with drug

> > companies.

> > > > >

> > > > > " The specter of a Democratic administration has

> > had some effect on the

> > > > > stocks, " Hazlett said.

> > > > > Politics aside, Lilly has struggled to keep

> > sales up and costs down.

> > > > >

> > > > > In the past two weeks, Lilly has announced it

> > would cut 1,000 jobs

> > from

> > > > its

> > > > > work force, which numbers 46,000 worldwide.

> > Lilly's operations in

> > > > > Indianapolis will absorb 225. Lilly also

> > instituted a hiring freeze in

> > > > > August.

> > > > >

> > > > > Those cost-cutting moves helped Lilly post a 6

> > percent increase in

> > > profits

> > > > > in its fiscal third quarter; revenue grew a

> > modest 4 percent, leaving

> > > Wall

> > > > > Street nonplussed.

> > > > >

> > > > > " The good news is management had the 'wiggle

> > room' -- the bad news is

> > > they

> > > > > needed it (and likely will continue to), " wrote

> > Carl Seiden, an

> > analyst

> > > > > covering Lilly for the brokerage firm UBS.

> > > > >

> > > > > Many analysts are worried by declining sales of

> > Lilly's blockbuster

> > > drug,

> > > > > Zyprexa. It generates more than $4 billion a

> > year for Lilly, and, by

> > > some

> > > > > analysts' estimates, accounts for 60 percent of

> > the company's profits.

> > > > >

> > > > > Sales of the antipsychotic drug fell 9 percent

> > in Lilly's third

> > quarter,

> > > > > including a 22 percent drop in the United

> > States. And the patent

> > > challenge

> > > > > brought against Zyprexa by a generic drug maker,

> > which is now in the

> > > hands

> > > > > of an Indianapolis judge, still hangs like a

> > cloud over Lilly.

> > > > >

> > > > > " We believe investors are better off on the

> > sidelines until the

> > > visibility

> > > > > on the Zyprexa controversies improve, " Seiden

> > wrote.

> > > > >

> > > > > Other analysts have been disappointed in early

> > sales of Lilly's newest

> > > > > drugs, such as Strattera, which is used in

> > treating attention-deficit

> > > > > hyperactivity disorder.

> > > > >

> > > > > But Hazlett takes a rosier view on Lilly. He

> > points to Cymbalta, an

> > > > > antidepressant Lilly rolled out this summer, as

> > evidence for his

> > > > prediction

> > > > > of strong profit growth the next two years.

> > > > >

> > > > > Hazlett wrote that he " would recommend that

> > investors use the recent

> > > > > weakness to establish or add to a position. "

> > > > >

> > > > > Star reporter O'Neal contributed to this

> > story.

> > > > > Call Star reporter J.K. Wall at (317) 444-6287.

> > > > >

October 27, 2004

Jim,

You're a little edge/

Haev a little anxiety?

Don'tn get along well with others?

Do you have whatever that syndrome they've named up to call people who have

the normal feeling of feeling uncomfortable going into a room of people?

Perhaps you need to try a litttle

zoloft

or diospen

depakote

seroquel

paxil

lithium

effexor

let's see I'm sure there's a couple they experimended on with myh Mother

that i've forgotten

try a few of those if you're cranky

they'll fix you right up.

Re: Lilly Stock Spirals

> > Down (Time for a little

> > > celebration!)

> > >

> > > >

> > > > I hate for people to lose jobs but I love this

> > news. goes to show

> > > > what unethical and harmful products will get a

> > business everytime.

> > > > Couldn't happen to a better bunch. Makes me think

> > carefully about

> > > > where I will work.

> > > >

> > > > >

> > http://www.indystar.com/articles/3/189440-8983-223.html

> > > > >

> > > > > Lilly stock spirals down

> > > > > The Indianapolis company's share price has hit a

> > 52-week low every day

> > > > since

> > > > > Oct. 19.

> > > > >

> > > > > By J.K. Wall

> > > > > jk.wall@...

> > > > > October 26, 2004

> > > > >

> > > > > Eli Lilly and Co. shares hit another 52-week low

> > Monday as the company

> > > > > continued to feel the fallout from its own weak

> > financial growth and

> > > that

> > > > of

> > > > > the whole pharmaceutical industry.

> > > > >

> > > > > Shares of the Indianapolis-based company have

> > fallen nearly 15 percent

> > > in

> > > > > the past two weeks, closing Monday at $50.44 a

> > share. The value has

> > > fallen

> > > > > by more than 28 percent since Jan. 1. Lilly

> > stock closed as high as

> > > $76.95

> > > > > in early June.

> > > > >

> > > > > The share price has hit a new 52-week low every

> > day since Oct. 19.

> > > Lilly,

> > > > > Central Indiana's largest private employer, last

> > week announced job

> > cuts

> > > > and

> > > > > reported sales that disappointed Wall Street

> > analysts.

> > > > >

> > > > > If the difficulties at Lilly are prolonged, they

> > could indirectly

> > affect

> > > > the

> > > > > Lilly Endowment, a massive Indianapolis

> > philanthropic foundation.

> > > > >

> > > > > While the $10.8 billion endowment is independent

> > of the drug maker,

> > > Lilly

> > > > > stock is the endowment's most significant asset.

> > > > >

> > > > > For now, however, the company's performance

> > should not change the

> > > > > endowment's level of giving, said an official

> > with the Indiana

> > > Grantmakers

> > > > > Alliance.

> > > > >

> > > > > " Private foundations are obligated to pay out at

> > least 5 percent of

> > > their

> > > > > assets. However, the 5 percent is based on a

> > three-year rolling

> > > average, "

> > > > > said Audette, vice president of the

> > alliance, in a written

> > > > > statement. " Therefore a spike one way or the

> > other in the market or in

> > a

> > > > > particular stock, even if a foundation is heavy

> > in that stock, has

> > > little

> > > > > effect on the long-term giving. "

> > > > > Other drug companies also aren't faring well on

> > Wall Street.

> > > > >

> > > > > Last week was the fifth straight that the

> > American Stock Exchange

> > > > > Pharmaceutical Index fell. The slide started

> > just before Merck & Co

> > Inc.

> > > > > announced that it would yank Vioxx, a popular

> > arthritis drug, from the

> > > > > market. Hazlett, a pharmaceuticals

> > analyst at SunTrust

> > > > > Humphrey, described that development as a

> > " disaster " for Merck that

> > has

> > > > > affected the entire industry.

> > > > >

> > > > > Pfizer, the world's largest drug maker,

> > disappointed investors last

> > week

> > > > > with revenues that missed analysts' estimates.

> > Its profits beat

> > > estimates

> > > > by

> > > > > a penny per share, but it also warned that next

> > year's results could

> > be

> > > > hurt

> > > > > by the arrival of generic competitors against

> > four of its drugs.

> > > > > GlaxoKline, which reports earnings

> > Thursday, faces several

> > cheaper

> > > > > copycat medications that will compete with its

> > compounds.

> > > > >

> > > > > In addition, Hazlett said, pharmaceutical

> > companies also fear that a

> > > > victory

> > > > > by presidential candidate Kerry would lead

> > to lower drug prices

> > and

> > > > > imported drugs from Canada. Kerry has said he

> > wants government health

> > > care

> > > > > programs to negotiate lower prices with drug

> > companies.

> > > > >

> > > > > " The specter of a Democratic administration has

> > had some effect on the

> > > > > stocks, " Hazlett said.

> > > > > Politics aside, Lilly has struggled to keep

> > sales up and costs down.

> > > > >

> > > > > In the past two weeks, Lilly has announced it

> > would cut 1,000 jobs

> > from

> > > > its

> > > > > work force, which numbers 46,000 worldwide.

> > Lilly's operations in

> > > > > Indianapolis will absorb 225. Lilly also

> > instituted a hiring freeze in

> > > > > August.

> > > > >

> > > > > Those cost-cutting moves helped Lilly post a 6

> > percent increase in

> > > profits

> > > > > in its fiscal third quarter; revenue grew a

> > modest 4 percent, leaving

> > > Wall

> > > > > Street nonplussed.

> > > > >

> > > > > " The good news is management had the 'wiggle

> > room' -- the bad news is

> > > they

> > > > > needed it (and likely will continue to), " wrote

> > Carl Seiden, an

> > analyst

> > > > > covering Lilly for the brokerage firm UBS.

> > > > >

> > > > > Many analysts are worried by declining sales of

> > Lilly's blockbuster

> > > drug,

> > > > > Zyprexa. It generates more than $4 billion a

> > year for Lilly, and, by

> > > some

> > > > > analysts' estimates, accounts for 60 percent of

> > the company's profits.

> > > > >

> > > > > Sales of the antipsychotic drug fell 9 percent

> > in Lilly's third

> > quarter,

> > > > > including a 22 percent drop in the United

> > States. And the patent

> > > challenge

> > > > > brought against Zyprexa by a generic drug maker,

> > which is now in the

> > > hands

> > > > > of an Indianapolis judge, still hangs like a

> > cloud over Lilly.

> > > > >

> > > > > " We believe investors are better off on the

> > sidelines until the

> > > visibility

> > > > > on the Zyprexa controversies improve, " Seiden

> > wrote.

> > > > >

> > > > > Other analysts have been disappointed in early

> > sales of Lilly's newest

> > > > > drugs, such as Strattera, which is used in

> > treating attention-deficit

> > > > > hyperactivity disorder.

> > > > >

> > > > > But Hazlett takes a rosier view on Lilly. He

> > points to Cymbalta, an

> > > > > antidepressant Lilly rolled out this summer, as

> > evidence for his

> > > > prediction

> > > > > of strong profit growth the next two years.

> > > > >

> > > > > Hazlett wrote that he " would recommend that

> > investors use the recent

> > > > > weakness to establish or add to a position. "

> > > > >

> > > > > Star reporter O'Neal contributed to this

> > story.

> > > > > Call Star reporter J.K. Wall at (317) 444-6287.

> > > > >

October 27, 2004

Jim,

You're a little edge/

Haev a little anxiety?

Don'tn get along well with others?

Do you have whatever that syndrome they've named up to call people who have

the normal feeling of feeling uncomfortable going into a room of people?

Perhaps you need to try a litttle

zoloft

or diospen

depakote

seroquel

paxil

lithium

effexor

let's see I'm sure there's a couple they experimended on with myh Mother

that i've forgotten

try a few of those if you're cranky

they'll fix you right up.

Re: Lilly Stock Spirals

> > Down (Time for a little

> > > celebration!)

> > >

> > > >

> > > > I hate for people to lose jobs but I love this

> > news. goes to show

> > > > what unethical and harmful products will get a

> > business everytime.

> > > > Couldn't happen to a better bunch. Makes me think

> > carefully about

> > > > where I will work.

> > > >

> > > > >

> > http://www.indystar.com/articles/3/189440-8983-223.html

> > > > >

> > > > > Lilly stock spirals down

> > > > > The Indianapolis company's share price has hit a

> > 52-week low every day

> > > > since

> > > > > Oct. 19.

> > > > >

> > > > > By J.K. Wall

> > > > > jk.wall@...

> > > > > October 26, 2004

> > > > >

> > > > > Eli Lilly and Co. shares hit another 52-week low

> > Monday as the company

> > > > > continued to feel the fallout from its own weak

> > financial growth and

> > > that

> > > > of

> > > > > the whole pharmaceutical industry.

> > > > >

> > > > > Shares of the Indianapolis-based company have

> > fallen nearly 15 percent

> > > in

> > > > > the past two weeks, closing Monday at $50.44 a

> > share. The value has

> > > fallen

> > > > > by more than 28 percent since Jan. 1. Lilly

> > stock closed as high as

> > > $76.95

> > > > > in early June.

> > > > >

> > > > > The share price has hit a new 52-week low every

> > day since Oct. 19.

> > > Lilly,

> > > > > Central Indiana's largest private employer, last

> > week announced job

> > cuts

> > > > and

> > > > > reported sales that disappointed Wall Street

> > analysts.

> > > > >

> > > > > If the difficulties at Lilly are prolonged, they

> > could indirectly

> > affect

> > > > the

> > > > > Lilly Endowment, a massive Indianapolis

> > philanthropic foundation.

> > > > >

> > > > > While the $10.8 billion endowment is independent

> > of the drug maker,

> > > Lilly

> > > > > stock is the endowment's most significant asset.

> > > > >

> > > > > For now, however, the company's performance

> > should not change the

> > > > > endowment's level of giving, said an official

> > with the Indiana

> > > Grantmakers

> > > > > Alliance.

> > > > >

> > > > > " Private foundations are obligated to pay out at

> > least 5 percent of

> > > their

> > > > > assets. However, the 5 percent is based on a

> > three-year rolling

> > > average, "

> > > > > said Audette, vice president of the

> > alliance, in a written

> > > > > statement. " Therefore a spike one way or the

> > other in the market or in

> > a

> > > > > particular stock, even if a foundation is heavy

> > in that stock, has

> > > little

> > > > > effect on the long-term giving. "

> > > > > Other drug companies also aren't faring well on

> > Wall Street.

> > > > >

> > > > > Last week was the fifth straight that the

> > American Stock Exchange

> > > > > Pharmaceutical Index fell. The slide started

> > just before Merck & Co

> > Inc.

> > > > > announced that it would yank Vioxx, a popular

> > arthritis drug, from the

> > > > > market. Hazlett, a pharmaceuticals

> > analyst at SunTrust

> > > > > Humphrey, described that development as a

> > " disaster " for Merck that

> > has

> > > > > affected the entire industry.

> > > > >

> > > > > Pfizer, the world's largest drug maker,

> > disappointed investors last

> > week

> > > > > with revenues that missed analysts' estimates.

> > Its profits beat

> > > estimates

> > > > by

> > > > > a penny per share, but it also warned that next

> > year's results could

> > be

> > > > hurt

> > > > > by the arrival of generic competitors against

> > four of its drugs.

> > > > > GlaxoKline, which reports earnings

> > Thursday, faces several

> > cheaper

> > > > > copycat medications that will compete with its

> > compounds.

> > > > >

> > > > > In addition, Hazlett said, pharmaceutical

> > companies also fear that a

> > > > victory

> > > > > by presidential candidate Kerry would lead

> > to lower drug prices

> > and

> > > > > imported drugs from Canada. Kerry has said he

> > wants government health

> > > care

> > > > > programs to negotiate lower prices with drug

> > companies.

> > > > >

> > > > > " The specter of a Democratic administration has

> > had some effect on the

> > > > > stocks, " Hazlett said.

> > > > > Politics aside, Lilly has struggled to keep

> > sales up and costs down.

> > > > >

> > > > > In the past two weeks, Lilly has announced it

> > would cut 1,000 jobs

> > from

> > > > its

> > > > > work force, which numbers 46,000 worldwide.

> > Lilly's operations in

> > > > > Indianapolis will absorb 225. Lilly also

> > instituted a hiring freeze in

> > > > > August.

> > > > >

> > > > > Those cost-cutting moves helped Lilly post a 6

> > percent increase in

> > > profits

> > > > > in its fiscal third quarter; revenue grew a

> > modest 4 percent, leaving

> > > Wall

> > > > > Street nonplussed.

> > > > >

> > > > > " The good news is management had the 'wiggle

> > room' -- the bad news is

> > > they

> > > > > needed it (and likely will continue to), " wrote

> > Carl Seiden, an

> > analyst

> > > > > covering Lilly for the brokerage firm UBS.

> > > > >

> > > > > Many analysts are worried by declining sales of

> > Lilly's blockbuster

> > > drug,

> > > > > Zyprexa. It generates more than $4 billion a

> > year for Lilly, and, by

> > > some

> > > > > analysts' estimates, accounts for 60 percent of

> > the company's profits.

> > > > >

> > > > > Sales of the antipsychotic drug fell 9 percent

> > in Lilly's third

> > quarter,

> > > > > including a 22 percent drop in the United

> > States. And the patent

> > > challenge

> > > > > brought against Zyprexa by a generic drug maker,

> > which is now in the

> > > hands

> > > > > of an Indianapolis judge, still hangs like a

> > cloud over Lilly.

> > > > >

> > > > > " We believe investors are better off on the

> > sidelines until the

> > > visibility

> > > > > on the Zyprexa controversies improve, " Seiden

> > wrote.

> > > > >

> > > > > Other analysts have been disappointed in early

> > sales of Lilly's newest

> > > > > drugs, such as Strattera, which is used in

> > treating attention-deficit

> > > > > hyperactivity disorder.

> > > > >

> > > > > But Hazlett takes a rosier view on Lilly. He

> > points to Cymbalta, an

> > > > > antidepressant Lilly rolled out this summer, as

> > evidence for his

> > > > prediction

> > > > > of strong profit growth the next two years.

> > > > >

> > > > > Hazlett wrote that he " would recommend that

> > investors use the recent

> > > > > weakness to establish or add to a position. "

> > > > >

> > > > > Star reporter O'Neal contributed to this

> > story.

> > > > > Call Star reporter J.K. Wall at (317) 444-6287.

> > > > >

October 27, 2004

Jim,

You're a little edge/

Haev a little anxiety?

Don'tn get along well with others?

Do you have whatever that syndrome they've named up to call people who have

the normal feeling of feeling uncomfortable going into a room of people?

Perhaps you need to try a litttle

zoloft

or diospen

depakote

seroquel

paxil

lithium

effexor

let's see I'm sure there's a couple they experimended on with myh Mother

that i've forgotten

try a few of those if you're cranky

they'll fix you right up.

Re: Lilly Stock Spirals

> > Down (Time for a little

> > > celebration!)

> > >

> > > >

> > > > I hate for people to lose jobs but I love this

> > news. goes to show

> > > > what unethical and harmful products will get a

> > business everytime.

> > > > Couldn't happen to a better bunch. Makes me think

> > carefully about

> > > > where I will work.

> > > >

> > > > >

> > http://www.indystar.com/articles/3/189440-8983-223.html

> > > > >

> > > > > Lilly stock spirals down

> > > > > The Indianapolis company's share price has hit a

> > 52-week low every day

> > > > since

> > > > > Oct. 19.

> > > > >

> > > > > By J.K. Wall

> > > > > jk.wall@...

> > > > > October 26, 2004

> > > > >

> > > > > Eli Lilly and Co. shares hit another 52-week low

> > Monday as the company

> > > > > continued to feel the fallout from its own weak

> > financial growth and

> > > that

> > > > of

> > > > > the whole pharmaceutical industry.

> > > > >

> > > > > Shares of the Indianapolis-based company have

> > fallen nearly 15 percent

> > > in

> > > > > the past two weeks, closing Monday at $50.44 a

> > share. The value has

> > > fallen

> > > > > by more than 28 percent since Jan. 1. Lilly

> > stock closed as high as

> > > $76.95

> > > > > in early June.

> > > > >

> > > > > The share price has hit a new 52-week low every

> > day since Oct. 19.

> > > Lilly,

> > > > > Central Indiana's largest private employer, last

> > week announced job

> > cuts

> > > > and

> > > > > reported sales that disappointed Wall Street

> > analysts.

> > > > >

> > > > > If the difficulties at Lilly are prolonged, they

> > could indirectly

> > affect

> > > > the

> > > > > Lilly Endowment, a massive Indianapolis

> > philanthropic foundation.

> > > > >

> > > > > While the $10.8 billion endowment is independent

> > of the drug maker,

> > > Lilly

> > > > > stock is the endowment's most significant asset.

> > > > >

> > > > > For now, however, the company's performance

> > should not change the

> > > > > endowment's level of giving, said an official

> > with the Indiana

> > > Grantmakers

> > > > > Alliance.

> > > > >

> > > > > " Private foundations are obligated to pay out at

> > least 5 percent of

> > > their

> > > > > assets. However, the 5 percent is based on a

> > three-year rolling

> > > average, "

> > > > > said Audette, vice president of the

> > alliance, in a written

> > > > > statement. " Therefore a spike one way or the

> > other in the market or in

> > a

> > > > > particular stock, even if a foundation is heavy

> > in that stock, has

> > > little

> > > > > effect on the long-term giving. "

> > > > > Other drug companies also aren't faring well on

> > Wall Street.

> > > > >

> > > > > Last week was the fifth straight that the

> > American Stock Exchange

> > > > > Pharmaceutical Index fell. The slide started

> > just before Merck & Co

> > Inc.

> > > > > announced that it would yank Vioxx, a popular

> > arthritis drug, from the

> > > > > market. Hazlett, a pharmaceuticals

> > analyst at SunTrust

> > > > > Humphrey, described that development as a

> > " disaster " for Merck that

> > has

> > > > > affected the entire industry.

> > > > >

> > > > > Pfizer, the world's largest drug maker,

> > disappointed investors last

> > week

> > > > > with revenues that missed analysts' estimates.

> > Its profits beat

> > > estimates

> > > > by

> > > > > a penny per share, but it also warned that next

> > year's results could

> > be

> > > > hurt

> > > > > by the arrival of generic competitors against

> > four of its drugs.

> > > > > GlaxoKline, which reports earnings

> > Thursday, faces several

> > cheaper

> > > > > copycat medications that will compete with its

> > compounds.

> > > > >

> > > > > In addition, Hazlett said, pharmaceutical

> > companies also fear that a

> > > > victory

> > > > > by presidential candidate Kerry would lead

> > to lower drug prices

> > and

> > > > > imported drugs from Canada. Kerry has said he

> > wants government health

> > > care

> > > > > programs to negotiate lower prices with drug

> > companies.

> > > > >

> > > > > " The specter of a Democratic administration has

> > had some effect on the

> > > > > stocks, " Hazlett said.

> > > > > Politics aside, Lilly has struggled to keep

> > sales up and costs down.

> > > > >

> > > > > In the past two weeks, Lilly has announced it

> > would cut 1,000 jobs

> > from

> > > > its

> > > > > work force, which numbers 46,000 worldwide.

> > Lilly's operations in

> > > > > Indianapolis will absorb 225. Lilly also

> > instituted a hiring freeze in

> > > > > August.

> > > > >

> > > > > Those cost-cutting moves helped Lilly post a 6

> > percent increase in

> > > profits

> > > > > in its fiscal third quarter; revenue grew a

> > modest 4 percent, leaving

> > > Wall

> > > > > Street nonplussed.

> > > > >

> > > > > " The good news is management had the 'wiggle

> > room' -- the bad news is

> > > they

> > > > > needed it (and likely will continue to), " wrote

> > Carl Seiden, an

> > analyst

> > > > > covering Lilly for the brokerage firm UBS.

> > > > >

> > > > > Many analysts are worried by declining sales of

> > Lilly's blockbuster

> > > drug,

> > > > > Zyprexa. It generates more than $4 billion a

> > year for Lilly, and, by

> > > some

> > > > > analysts' estimates, accounts for 60 percent of

> > the company's profits.

> > > > >

> > > > > Sales of the antipsychotic drug fell 9 percent

> > in Lilly's third

> > quarter,

> > > > > including a 22 percent drop in the United

> > States. And the patent

> > > challenge

> > > > > brought against Zyprexa by a generic drug maker,

> > which is now in the

> > > hands

> > > > > of an Indianapolis judge, still hangs like a

> > cloud over Lilly.

> > > > >

> > > > > " We believe investors are better off on the

> > sidelines until the

> > > visibility

> > > > > on the Zyprexa controversies improve, " Seiden

> > wrote.

> > > > >

> > > > > Other analysts have been disappointed in early

> > sales of Lilly's newest

> > > > > drugs, such as Strattera, which is used in

> > treating attention-deficit

> > > > > hyperactivity disorder.

> > > > >

> > > > > But Hazlett takes a rosier view on Lilly. He

> > points to Cymbalta, an

> > > > > antidepressant Lilly rolled out this summer, as

> > evidence for his

> > > > prediction

> > > > > of strong profit growth the next two years.

> > > > >

> > > > > Hazlett wrote that he " would recommend that

> > investors use the recent

> > > > > weakness to establish or add to a position. "

> > > > >

> > > > > Star reporter O'Neal contributed to this

> > story.

> > > > > Call Star reporter J.K. Wall at (317) 444-6287.

> > > > >

October 27, 2004

Jim, you're simply suffering from Pre-Election Anxiety Disorder!!!

>From: " Jim " <mofunnow@...>

>Reply-SSRI medications

><SSRI medications >

>Subject: Re: Lilly Stock Spirals Down (Time for a little

>celebration!)

>Date: Wed, 27 Oct 2004 15:05:26 -0500

>

October 27, 2004

Jim, you're simply suffering from Pre-Election Anxiety Disorder!!!

>From: " Jim " <mofunnow@...>

>Reply-SSRI medications

><SSRI medications >

>Subject: Re: Lilly Stock Spirals Down (Time for a little

>celebration!)

>Date: Wed, 27 Oct 2004 15:05:26 -0500

>

October 27, 2004

Yeah I better run down to my closest psychiatrist and get doped. NOT!

I had lunch and some calcium/magnesium and feeling much better now

A walk and some sleep will do me good tonight.

Jim

Re: Lilly Stock Spirals

> > > Down (Time for a little

> > > > celebration!)

> > > >

> > > > >

> > > > > I hate for people to lose jobs but I love this

> > > news. goes to show

> > > > > what unethical and harmful products will get a

> > > business everytime.

> > > > > Couldn't happen to a better bunch. Makes me think

> > > carefully about

> > > > > where I will work.

> > > > >

> > > > > >

> > > http://www.indystar.com/articles/3/189440-8983-223.html

> > > > > >

> > > > > > Lilly stock spirals down

> > > > > > The Indianapolis company's share price has hit a

> > > 52-week low every day

> > > > > since

> > > > > > Oct. 19.

> > > > > >

> > > > > > By J.K. Wall

> > > > > > jk.wall@...

> > > > > > October 26, 2004

> > > > > >

> > > > > > Eli Lilly and Co. shares hit another 52-week low

> > > Monday as the company

> > > > > > continued to feel the fallout from its own weak

> > > financial growth and

> > > > that

> > > > > of

> > > > > > the whole pharmaceutical industry.

> > > > > >

> > > > > > Shares of the Indianapolis-based company have

> > > fallen nearly 15 percent

> > > > in

> > > > > > the past two weeks, closing Monday at $50.44 a

> > > share. The value has

> > > > fallen

> > > > > > by more than 28 percent since Jan. 1. Lilly

> > > stock closed as high as

> > > > $76.95

> > > > > > in early June.

> > > > > >

> > > > > > The share price has hit a new 52-week low every

> > > day since Oct. 19.

> > > > Lilly,

> > > > > > Central Indiana's largest private employer, last

> > > week announced job

> > > cuts

> > > > > and

> > > > > > reported sales that disappointed Wall Street

> > > analysts.

> > > > > >

> > > > > > If the difficulties at Lilly are prolonged, they

> > > could indirectly

> > > affect

> > > > > the

> > > > > > Lilly Endowment, a massive Indianapolis

> > > philanthropic foundation.

> > > > > >

> > > > > > While the $10.8 billion endowment is independent

> > > of the drug maker,

> > > > Lilly

> > > > > > stock is the endowment's most significant asset.

> > > > > >

> > > > > > For now, however, the company's performance

> > > should not change the

> > > > > > endowment's level of giving, said an official

> > > with the Indiana

> > > > Grantmakers

> > > > > > Alliance.

> > > > > >

> > > > > > " Private foundations are obligated to pay out at

> > > least 5 percent of

> > > > their

> > > > > > assets. However, the 5 percent is based on a

> > > three-year rolling

> > > > average, "

> > > > > > said Audette, vice president of the

> > > alliance, in a written

> > > > > > statement. " Therefore a spike one way or the

> > > other in the market or in

> > > a

> > > > > > particular stock, even if a foundation is heavy

> > > in that stock, has

> > > > little

> > > > > > effect on the long-term giving. "

> > > > > > Other drug companies also aren't faring well on

> > > Wall Street.

> > > > > >

> > > > > > Last week was the fifth straight that the

> > > American Stock Exchange

> > > > > > Pharmaceutical Index fell. The slide started

> > > just before Merck & Co

> > > Inc.

> > > > > > announced that it would yank Vioxx, a popular

> > > arthritis drug, from the

> > > > > > market. Hazlett, a pharmaceuticals

> > > analyst at SunTrust

> > > > > > Humphrey, described that development as a

> > > " disaster " for Merck that

> > > has

> > > > > > affected the entire industry.

> > > > > >

> > > > > > Pfizer, the world's largest drug maker,

> > > disappointed investors last

> > > week

> > > > > > with revenues that missed analysts' estimates.

> > > Its profits beat

> > > > estimates

> > > > > by

> > > > > > a penny per share, but it also warned that next

> > > year's results could

> > > be

> > > > > hurt

> > > > > > by the arrival of generic competitors against

> > > four of its drugs.

> > > > > > GlaxoKline, which reports earnings

> > > Thursday, faces several

> > > cheaper

> > > > > > copycat medications that will compete with its

> > > compounds.

> > > > > >

> > > > > > In addition, Hazlett said, pharmaceutical

> > > companies also fear that a

> > > > > victory

> > > > > > by presidential candidate Kerry would lead

> > > to lower drug prices

> > > and

> > > > > > imported drugs from Canada. Kerry has said he

> > > wants government health

> > > > care

> > > > > > programs to negotiate lower prices with drug

> > > companies.

> > > > > >

> > > > > > " The specter of a Democratic administration has

> > > had some effect on the

> > > > > > stocks, " Hazlett said.

> > > > > > Politics aside, Lilly has struggled to keep

> > > sales up and costs down.

> > > > > >

> > > > > > In the past two weeks, Lilly has announced it

> > > would cut 1,000 jobs

> > > from

> > > > > its

> > > > > > work force, which numbers 46,000 worldwide.

> > > Lilly's operations in

> > > > > > Indianapolis will absorb 225. Lilly also

> > > instituted a hiring freeze in

> > > > > > August.

> > > > > >

> > > > > > Those cost-cutting moves helped Lilly post a 6

> > > percent increase in

> > > > profits

> > > > > > in its fiscal third quarter; revenue grew a

> > > modest 4 percent, leaving

> > > > Wall

> > > > > > Street nonplussed.

> > > > > >

> > > > > > " The good news is management had the 'wiggle

> > > room' -- the bad news is

> > > > they

> > > > > > needed it (and likely will continue to), " wrote

> > > Carl Seiden, an

> > > analyst

> > > > > > covering Lilly for the brokerage firm UBS.

> > > > > >

> > > > > > Many analysts are worried by declining sales of

> > > Lilly's blockbuster

> > > > drug,

> > > > > > Zyprexa. It generates more than $4 billion a

> > > year for Lilly, and, by

> > > > some

> > > > > > analysts' estimates, accounts for 60 percent of

> > > the company's profits.

> > > > > >

> > > > > > Sales of the antipsychotic drug fell 9 percent

> > > in Lilly's third

> > > quarter,

> > > > > > including a 22 percent drop in the United

> > > States. And the patent

> > > > challenge

> > > > > > brought against Zyprexa by a generic drug maker,

> > > which is now in the

> > > > hands

> > > > > > of an Indianapolis judge, still hangs like a

> > > cloud over Lilly.

> > > > > >

> > > > > > " We believe investors are better off on the

> > > sidelines until the

> > > > visibility

> > > > > > on the Zyprexa controversies improve, " Seiden

> > > wrote.

> > > > > >

> > > > > > Other analysts have been disappointed in early

> > > sales of Lilly's newest

> > > > > > drugs, such as Strattera, which is used in

> > > treating attention-deficit

> > > > > > hyperactivity disorder.

> > > > > >

> > > > > > But Hazlett takes a rosier view on Lilly. He

> > > points to Cymbalta, an

> > > > > > antidepressant Lilly rolled out this summer, as

> > > evidence for his

> > > > > prediction

> > > > > > of strong profit growth the next two years.

> > > > > >

> > > > > > Hazlett wrote that he " would recommend that

> > > investors use the recent

> > > > > > weakness to establish or add to a position. "

> > > > > >

> > > > > > Star reporter O'Neal contributed to this

> > > story.

> > > > > > Call Star reporter J.K. Wall at (317) 444-6287.

> > > > > >

October 27, 2004

Yeah I better run down to my closest psychiatrist and get doped. NOT!

I had lunch and some calcium/magnesium and feeling much better now

A walk and some sleep will do me good tonight.

Jim

Re: Lilly Stock Spirals

> > > Down (Time for a little

> > > > celebration!)

> > > >

> > > > >

> > > > > I hate for people to lose jobs but I love this

> > > news. goes to show

> > > > > what unethical and harmful products will get a

> > > business everytime.

> > > > > Couldn't happen to a better bunch. Makes me think

> > > carefully about

> > > > > where I will work.

> > > > >

> > > > > >

> > > http://www.indystar.com/articles/3/189440-8983-223.html

> > > > > >

> > > > > > Lilly stock spirals down

> > > > > > The Indianapolis company's share price has hit a

> > > 52-week low every day

> > > > > since

> > > > > > Oct. 19.

> > > > > >

> > > > > > By J.K. Wall

> > > > > > jk.wall@...

> > > > > > October 26, 2004

> > > > > >

> > > > > > Eli Lilly and Co. shares hit another 52-week low

> > > Monday as the company

> > > > > > continued to feel the fallout from its own weak

> > > financial growth and

> > > > that

> > > > > of

> > > > > > the whole pharmaceutical industry.

> > > > > >

> > > > > > Shares of the Indianapolis-based company have

> > > fallen nearly 15 percent

> > > > in

> > > > > > the past two weeks, closing Monday at $50.44 a

> > > share. The value has

> > > > fallen

> > > > > > by more than 28 percent since Jan. 1. Lilly

> > > stock closed as high as

> > > > $76.95

> > > > > > in early June.

> > > > > >

> > > > > > The share price has hit a new 52-week low every

> > > day since Oct. 19.

> > > > Lilly,

> > > > > > Central Indiana's largest private employer, last

> > > week announced job

> > > cuts

> > > > > and

> > > > > > reported sales that disappointed Wall Street

> > > analysts.

> > > > > >

> > > > > > If the difficulties at Lilly are prolonged, they

> > > could indirectly

> > > affect

> > > > > the

> > > > > > Lilly Endowment, a massive Indianapolis

> > > philanthropic foundation.

> > > > > >

> > > > > > While the $10.8 billion endowment is independent

> > > of the drug maker,

> > > > Lilly

> > > > > > stock is the endowment's most significant asset.

> > > > > >

> > > > > > For now, however, the company's performance

> > > should not change the

> > > > > > endowment's level of giving, said an official

> > > with the Indiana

> > > > Grantmakers

> > > > > > Alliance.

> > > > > >

> > > > > > " Private foundations are obligated to pay out at

> > > least 5 percent of

> > > > their

> > > > > > assets. However, the 5 percent is based on a

> > > three-year rolling

> > > > average, "

> > > > > > said Audette, vice president of the

> > > alliance, in a written

> > > > > > statement. " Therefore a spike one way or the

> > > other in the market or in

> > > a

> > > > > > particular stock, even if a foundation is heavy

> > > in that stock, has

> > > > little

> > > > > > effect on the long-term giving. "

> > > > > > Other drug companies also aren't faring well on

> > > Wall Street.

> > > > > >

> > > > > > Last week was the fifth straight that the

> > > American Stock Exchange

> > > > > > Pharmaceutical Index fell. The slide started

> > > just before Merck & Co

> > > Inc.

> > > > > > announced that it would yank Vioxx, a popular

> > > arthritis drug, from the

> > > > > > market. Hazlett, a pharmaceuticals

> > > analyst at SunTrust

> > > > > > Humphrey, described that development as a

> > > " disaster " for Merck that

> > > has

> > > > > > affected the entire industry.

> > > > > >

> > > > > > Pfizer, the world's largest drug maker,

> > > disappointed investors last

> > > week

> > > > > > with revenues that missed analysts' estimates.

> > > Its profits beat

> > > > estimates

> > > > > by

> > > > > > a penny per share, but it also warned that next

> > > year's results could

> > > be

> > > > > hurt

> > > > > > by the arrival of generic competitors against

> > > four of its drugs.

> > > > > > GlaxoKline, which reports earnings

> > > Thursday, faces several

> > > cheaper

> > > > > > copycat medications that will compete with its

> > > compounds.

> > > > > >

> > > > > > In addition, Hazlett said, pharmaceutical

> > > companies also fear that a

> > > > > victory

> > > > > > by presidential candidate Kerry would lead

> > > to lower drug prices

> > > and

> > > > > > imported drugs from Canada. Kerry has said he

> > > wants government health

> > > > care

> > > > > > programs to negotiate lower prices with drug

> > > companies.

> > > > > >

> > > > > > " The specter of a Democratic administration has

> > > had some effect on the

> > > > > > stocks, " Hazlett said.

> > > > > > Politics aside, Lilly has struggled to keep

> > > sales up and costs down.

> > > > > >

> > > > > > In the past two weeks, Lilly has announced it

> > > would cut 1,000 jobs

> > > from

> > > > > its

> > > > > > work force, which numbers 46,000 worldwide.

> > > Lilly's operations in

> > > > > > Indianapolis will absorb 225. Lilly also

> > > instituted a hiring freeze in

> > > > > > August.

> > > > > >

> > > > > > Those cost-cutting moves helped Lilly post a 6

> > > percent increase in

> > > > profits

> > > > > > in its fiscal third quarter; revenue grew a

> > > modest 4 percent, leaving

> > > > Wall

> > > > > > Street nonplussed.

> > > > > >

> > > > > > " The good news is management had the 'wiggle

> > > room' -- the bad news is

> > > > they

> > > > > > needed it (and likely will continue to), " wrote

> > > Carl Seiden, an

> > > analyst

> > > > > > covering Lilly for the brokerage firm UBS.

> > > > > >

> > > > > > Many analysts are worried by declining sales of

> > > Lilly's blockbuster

> > > > drug,

> > > > > > Zyprexa. It generates more than $4 billion a

> > > year for Lilly, and, by

> > > > some

> > > > > > analysts' estimates, accounts for 60 percent of

> > > the company's profits.

> > > > > >

> > > > > > Sales of the antipsychotic drug fell 9 percent

> > > in Lilly's third

> > > quarter,

> > > > > > including a 22 percent drop in the United

> > > States. And the patent

> > > > challenge

> > > > > > brought against Zyprexa by a generic drug maker,

> > > which is now in the

> > > > hands

> > > > > > of an Indianapolis judge, still hangs like a

> > > cloud over Lilly.

> > > > > >

> > > > > > " We believe investors are better off on the

> > > sidelines until the

> > > > visibility

> > > > > > on the Zyprexa controversies improve, " Seiden

> > > wrote.

> > > > > >

> > > > > > Other analysts have been disappointed in early

> > > sales of Lilly's newest

> > > > > > drugs, such as Strattera, which is used in

> > > treating attention-deficit

> > > > > > hyperactivity disorder.

> > > > > >

> > > > > > But Hazlett takes a rosier view on Lilly. He

> > > points to Cymbalta, an

> > > > > > antidepressant Lilly rolled out this summer, as

> > > evidence for his

> > > > > prediction

> > > > > > of strong profit growth the next two years.

> > > > > >

> > > > > > Hazlett wrote that he " would recommend that

> > > investors use the recent

> > > > > > weakness to establish or add to a position. "

> > > > > >

> > > > > > Star reporter O'Neal contributed to this

> > > story.

> > > > > > Call Star reporter J.K. Wall at (317) 444-6287.

> > > > > >

October 27, 2004

lolo, to funny!!! You guys are a hoot! lol

Thanks for that one doc.

Connie

lololol Cheers!

--- Jim <mofunnow@...> wrote:

---------------------------------

Yeah I better run down to my closest psychiatrist and

get doped. NOT!

I had lunch and some calcium/magnesium and feeling

much better now

A walk and some sleep will do me good tonight.

Jim

Re: Lilly Stock

Spirals

> > > Down (Time for a little

> > > > celebration!)

> > > >

> > > > >

> > > > > I hate for people to lose jobs but I love

this

> > > news. goes to show

> > > > > what unethical and harmful products will get

a

> > > business everytime.

> > > > > Couldn't happen to a better bunch. Makes me

think

> > > carefully about

> > > > > where I will work.

> > > > >

> > > > > >

> > >

http://www.indystar.com/articles/3/189440-8983-223.html

> > > > > >

> > > > > > Lilly stock spirals down

> > > > > > The Indianapolis company's share price has

hit a

> > > 52-week low every day

> > > > > since

> > > > > > Oct. 19.

> > > > > >

> > > > > > By J.K. Wall

> > > > > > jk.wall@...

> > > > > > October 26, 2004

> > > > > >

> > > > > > Eli Lilly and Co. shares hit another

52-week low

> > > Monday as the company

> > > > > > continued to feel the fallout from its own

weak

> > > financial growth and

> > > > that

> > > > > of

> > > > > > the whole pharmaceutical industry.

> > > > > >

> > > > > > Shares of the Indianapolis-based company

have

> > > fallen nearly 15 percent

> > > > in

> > > > > > the past two weeks, closing Monday at

$50.44 a

> > > share. The value has

> > > > fallen

> > > > > > by more than 28 percent since Jan. 1.

Lilly

> > > stock closed as high as

> > > > $76.95

> > > > > > in early June.

> > > > > >

> > > > > > The share price has hit a new 52-week low

every

> > > day since Oct. 19.

> > > > Lilly,

> > > > > > Central Indiana's largest private

employer, last

> > > week announced job

> > > cuts

> > > > > and

> > > > > > reported sales that disappointed Wall

Street

> > > analysts.

> > > > > >

> > > > > > If the difficulties at Lilly are

prolonged, they

> > > could indirectly

> > > affect

> > > > > the

> > > > > > Lilly Endowment, a massive Indianapolis

> > > philanthropic foundation.

> > > > > >

> > > > > > While the $10.8 billion endowment is

independent

> > > of the drug maker,

> > > > Lilly

> > > > > > stock is the endowment's most significant

asset.

> > > > > >

> > > > > > For now, however, the company's

performance

> > > should not change the

> > > > > > endowment's level of giving, said an

official

> > > with the Indiana

> > > > Grantmakers

> > > > > > Alliance.

> > > > > >

> > > > > > " Private foundations are obligated to pay

out at

> > > least 5 percent of

> > > > their

> > > > > > assets. However, the 5 percent is based on

a

> > > three-year rolling

> > > > average, "

> > > > > > said Audette, vice president of

the

> > > alliance, in a written

> > > > > > statement. " Therefore a spike one way or

the

> > > other in the market or in

> > > a

> > > > > > particular stock, even if a foundation is

heavy

> > > in that stock, has

> > > > little

> > > > > > effect on the long-term giving. "

> > > > > > Other drug companies also aren't faring

well on

> > > Wall Street.

> > > > > >

> > > > > > Last week was the fifth straight that the

> > > American Stock Exchange

> > > > > > Pharmaceutical Index fell. The slide

started

> > > just before Merck & Co

> > > Inc.

> > > > > > announced that it would yank Vioxx, a

popular

> > > arthritis drug, from the

> > > > > > market. Hazlett, a pharmaceuticals

> > > analyst at SunTrust

> > > > > > Humphrey, described that development as a

> > > " disaster " for Merck that

> > > has

> > > > > > affected the entire industry.

> > > > > >

> > > > > > Pfizer, the world's largest drug maker,

> > > disappointed investors last

> > > week

> > > > > > with revenues that missed analysts'

estimates.

> > > Its profits beat

> > > > estimates

> > > > > by

> > > > > > a penny per share, but it also warned that

> > > be

> > > > > hurt

> > > > > > by the arrival of generic competitors

against

> > > four of its drugs.

> > > > > > GlaxoKline, which reports earnings

> > > Thursday, faces several

> > > cheaper

> > > > > > copycat medications that will compete with

its

> > > compounds.

> > > > > >

> > > > > > In addition, Hazlett said, pharmaceutical

> > > companies also fear that a

> > > > > victory

> > > > > > by presidential candidate Kerry would

lead

> > > to lower drug prices

> > > and

> > > > > > imported drugs from Canada. Kerry has said

he

> > > wants government health

> > > > care

> > > > > > programs to negotiate lower prices with

drug

> > > companies.

> > > > > >

> > > > > > " The specter of a Democratic

administration has

> > > had some effect on the

> > > > > > stocks, " Hazlett said.

> > > > > > Politics aside, Lilly has struggled to

keep

> > > sales up and costs down.

> > > > > >

> > > > > > In the past two weeks, Lilly has announced

it

> > > would cut 1,000 jobs

> > > from

> > > > > its

> > > > > > work force, which numbers 46,000

worldwide.

> > > Lilly's operations in

> > > > > > Indianapolis will absorb 225. Lilly also

> > > instituted a hiring freeze in

> > > > > > August.

> > > > > >

> > > > > > Those cost-cutting moves helped Lilly post

a 6

> > > percent increase in

> > > > profits

> > > > > > in its fiscal third quarter; revenue grew

a

> > > modest 4 percent, leaving

> > > > Wall

> > > > > > Street nonplussed.

> > > > > >

> > > > > > " The good news is management had the

'wiggle

> > > room' -- the bad news is

> > > > they

> > > > > > needed it (and likely will continue to), "

wrote

> > > Carl Seiden, an

> > > analyst

> > > > > > covering Lilly for the brokerage firm UBS.

> > > > > >

> > > > > > Many analysts are worried by declining

sales of

> > > Lilly's blockbuster

> > > > drug,

> > > > > > Zyprexa. It generates more than $4 billion

a

> > > year for Lilly, and, by

> > > > some

> > > > > > analysts' estimates, accounts for 60

percent of

> > > the company's profits.

> > > > > >

> > > > > > Sales of the antipsychotic drug fell 9

percent

> > > in Lilly's third

> > > quarter,

> > > > > > including a 22 percent drop in the United

> > > States. And the patent

> > > > challenge

> > > > > > brought against Zyprexa by a generic drug

maker,

> > > which is now in the

> > > > hands

> > > > > > of an Indianapolis judge, still hangs like

a

> > > cloud over Lilly.

> > > > > >

> > > > > > " We believe investors are better off on

the

> > > sidelines until the

> > > > visibility

> > > > > > on the Zyprexa controversies improve, "

Seiden

> > > wrote.

> > > > > >

> > > > > > Other analysts have been disappointed in

early

> > > sales of Lilly's newest

> > > > > > drugs, such as Strattera, which is used in

> > > treating attention-deficit

> > > > > > hyperactivity disorder.

> > > > > >

> > > > > > But Hazlett takes a rosier view on Lilly.

He

> > > points to Cymbalta, an

> > > > > > antidepressant Lilly rolled out this

summer, as

> > > evidence for his

> > > > > prediction

> > > > > > of strong profit growth the next two

years.

> > > > > >

> > > > > > Hazlett wrote that he " would recommend

that

> > > investors use the recent

> > > > > > weakness to establish or add to a

position. "

> > > > > >

> > > > > > Star reporter O'Neal contributed to

this

> > > story.

> > > > > > Call Star reporter J.K. Wall at (317)

444-6287.

> > > > > >

October 27, 2004

lolo, to funny!!! You guys are a hoot! lol

Thanks for that one doc.

Connie

lololol Cheers!

--- Jim <mofunnow@...> wrote:

---------------------------------

Yeah I better run down to my closest psychiatrist and

get doped. NOT!

I had lunch and some calcium/magnesium and feeling

much better now

A walk and some sleep will do me good tonight.

Jim

Re: Lilly Stock

Spirals

> > > Down (Time for a little

> > > > celebration!)

> > > >

> > > > >

> > > > > I hate for people to lose jobs but I love

this

> > > news. goes to show

> > > > > what unethical and harmful products will get

a

> > > business everytime.

> > > > > Couldn't happen to a better bunch. Makes me

think

> > > carefully about

> > > > > where I will work.

> > > > >

> > > > > >

> > >

http://www.indystar.com/articles/3/189440-8983-223.html

> > > > > >

> > > > > > Lilly stock spirals down

> > > > > > The Indianapolis company's share price has

hit a

> > > 52-week low every day

> > > > > since

> > > > > > Oct. 19.

> > > > > >

> > > > > > By J.K. Wall

> > > > > > jk.wall@...

> > > > > > October 26, 2004

> > > > > >

> > > > > > Eli Lilly and Co. shares hit another

52-week low

> > > Monday as the company

> > > > > > continued to feel the fallout from its own

weak

> > > financial growth and

> > > > that

> > > > > of

> > > > > > the whole pharmaceutical industry.

> > > > > >

> > > > > > Shares of the Indianapolis-based company

have

> > > fallen nearly 15 percent

> > > > in

> > > > > > the past two weeks, closing Monday at

$50.44 a

> > > share. The value has

> > > > fallen

> > > > > > by more than 28 percent since Jan. 1.

Lilly

> > > stock closed as high as

> > > > $76.95

> > > > > > in early June.

> > > > > >

> > > > > > The share price has hit a new 52-week low

every

> > > day since Oct. 19.

> > > > Lilly,

> > > > > > Central Indiana's largest private

employer, last

> > > week announced job

> > > cuts

> > > > > and

> > > > > > reported sales that disappointed Wall

Street

> > > analysts.

> > > > > >

> > > > > > If the difficulties at Lilly are

prolonged, they

> > > could indirectly

> > > affect

> > > > > the

> > > > > > Lilly Endowment, a massive Indianapolis

> > > philanthropic foundation.

> > > > > >

> > > > > > While the $10.8 billion endowment is

independent

> > > of the drug maker,

> > > > Lilly

> > > > > > stock is the endowment's most significant

asset.

> > > > > >

> > > > > > For now, however, the company's

performance

> > > should not change the

> > > > > > endowment's level of giving, said an

official

> > > with the Indiana

> > > > Grantmakers

> > > > > > Alliance.

> > > > > >

> > > > > > " Private foundations are obligated to pay

out at

> > > least 5 percent of

> > > > their

> > > > > > assets. However, the 5 percent is based on

a

> > > three-year rolling

> > > > average, "

> > > > > > said Audette, vice president of

the

> > > alliance, in a written

> > > > > > statement. " Therefore a spike one way or

the

> > > other in the market or in

> > > a

> > > > > > particular stock, even if a foundation is

heavy

> > > in that stock, has

> > > > little

> > > > > > effect on the long-term giving. "

> > > > > > Other drug companies also aren't faring

well on

> > > Wall Street.

> > > > > >

> > > > > > Last week was the fifth straight that the

> > > American Stock Exchange

> > > > > > Pharmaceutical Index fell. The slide

started

> > > just before Merck & Co

> > > Inc.

> > > > > > announced that it would yank Vioxx, a

popular

> > > arthritis drug, from the

> > > > > > market. Hazlett, a pharmaceuticals

> > > analyst at SunTrust

> > > > > > Humphrey, described that development as a

> > > " disaster " for Merck that

> > > has

> > > > > > affected the entire industry.

> > > > > >

> > > > > > Pfizer, the world's largest drug maker,

> > > disappointed investors last

> > > week

> > > > > > with revenues that missed analysts'

estimates.

> > > Its profits beat

> > > > estimates

> > > > > by

> > > > > > a penny per share, but it also warned that

> > > be

> > > > > hurt

> > > > > > by the arrival of generic competitors

against

> > > four of its drugs.

> > > > > > GlaxoKline, which reports earnings

> > > Thursday, faces several

> > > cheaper

> > > > > > copycat medications that will compete with

its

> > > compounds.

> > > > > >

> > > > > > In addition, Hazlett said, pharmaceutical

> > > companies also fear that a

> > > > > victory

> > > > > > by presidential candidate Kerry would

lead

> > > to lower drug prices

> > > and

> > > > > > imported drugs from Canada. Kerry has said

he

> > > wants government health

> > > > care

> > > > > > programs to negotiate lower prices with

drug

> > > companies.

> > > > > >

> > > > > > " The specter of a Democratic

administration has

> > > had some effect on the

> > > > > > stocks, " Hazlett said.

> > > > > > Politics aside, Lilly has struggled to

keep

> > > sales up and costs down.

> > > > > >

> > > > > > In the past two weeks, Lilly has announced

it

> > > would cut 1,000 jobs

> > > from

> > > > > its

> > > > > > work force, which numbers 46,000

worldwide.

> > > Lilly's operations in

> > > > > > Indianapolis will absorb 225. Lilly also

> > > instituted a hiring freeze in

> > > > > > August.

> > > > > >

> > > > > > Those cost-cutting moves helped Lilly post

a 6

> > > percent increase in

> > > > profits

> > > > > > in its fiscal third quarter; revenue grew

a

> > > modest 4 percent, leaving

> > > > Wall

> > > > > > Street nonplussed.

> > > > > >

> > > > > > " The good news is management had the

'wiggle

> > > room' -- the bad news is

> > > > they

> > > > > > needed it (and likely will continue to), "

wrote

> > > Carl Seiden, an

> > > analyst

> > > > > > covering Lilly for the brokerage firm UBS.

> > > > > >

> > > > > > Many analysts are worried by declining

sales of

> > > Lilly's blockbuster

> > > > drug,

> > > > > > Zyprexa. It generates more than $4 billion

a

> > > year for Lilly, and, by

> > > > some

> > > > > > analysts' estimates, accounts for 60

percent of

> > > the company's profits.

> > > > > >

> > > > > > Sales of the antipsychotic drug fell 9

percent

> > > in Lilly's third

> > > quarter,

> > > > > > including a 22 percent drop in the United

> > > States. And the patent

> > > > challenge

> > > > > > brought against Zyprexa by a generic drug

maker,

> > > which is now in the

> > > > hands

> > > > > > of an Indianapolis judge, still hangs like

a

> > > cloud over Lilly.

> > > > > >

> > > > > > " We believe investors are better off on

the

> > > sidelines until the

> > > > visibility

> > > > > > on the Zyprexa controversies improve, "

Seiden

> > > wrote.

> > > > > >

> > > > > > Other analysts have been disappointed in

early

> > > sales of Lilly's newest

> > > > > > drugs, such as Strattera, which is used in

> > > treating attention-deficit

> > > > > > hyperactivity disorder.

> > > > > >

> > > > > > But Hazlett takes a rosier view on Lilly.

He

> > > points to Cymbalta, an

> > > > > > antidepressant Lilly rolled out this

summer, as

> > > evidence for his

> > > > > prediction

> > > > > > of strong profit growth the next two

years.

> > > > > >

> > > > > > Hazlett wrote that he " would recommend

that

> > > investors use the recent

> > > > > > weakness to establish or add to a

position. "

> > > > > >

> > > > > > Star reporter O'Neal contributed to

this

> > > story.

> > > > > > Call Star reporter J.K. Wall at (317)

444-6287.

> > > > > >

October 27, 2004

Roflol! That's a new one .. only don't give the New Freedom Commission any

ideas. Please!

Re: Lilly Stock Spirals Down (Time for a little

> >celebration!)

> >Date: Wed, 27 Oct 2004 15:05:26 -0500

> >

>

Sign In

Re: Lilly Stock Spirals Down (Time for a little celebration!)

Recommended Posts

Guest guest

Guest guest

Guest guest

Guest guest

Guest guest

Guest guest

Guest guest

Guest guest

Guest guest

Guest guest

Guest guest

Guest guest

Guest guest

Guest guest

Guest guest

Guest guest

Guest guest

Guest guest

Guest guest

Guest guest

Guest guest

Guest guest

Guest guest

Guest guest

Guest guest

Join the conversation

Activity